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ABSTRACT 
Routes to mononuclear Os(II) and Os(0) cluster complexes containing P-donor ligands (PR3, 
PP) were studied using the osmium salts Y2[OsX6] (Y = NH4, K; X = Cl, Br, I) as 
precursors. 
Carbonylation of the precursors and then subsequent reaction with tertiary phosphines afford 
neutral complexes of the type cis,cis,trans-[OsX2(CO)2(PR3)2] (X = Cl, Br, I, PR3 = tertiary 
phosphine), which were characterized by combination of infrared and Raman spectroscopy, 
NMR (
1
H, 
13
C, 
31
P) spectroscopy and elemental analysis. The compounds  cis,cis,trans-
[OsBr2(CO)2{Ph2P(CH2C6H5)}2] (2b), cis,cis,trans-[OsBr2(CO)2{P(CH2C6H5)}3] (3b) and 
cis,cis,trans-[OsBr2(CO)2{P(C6H11)}2] (4b) have been further characterized by single crystal 
X-ray diffraction. Thermogravimetric analysis of these complexes shows multiple stages of 
decomposition that can be directly related to the loss of ligands. 
 
Microwave-promoted reaction of the osmium salt precursor with bidentate phosphine ligands 
affords the neutral complexes [OsX2(PP)2] (X = Cl, Br, I; PP = bidentate phosphine 
ligand). A stepwise substitution pathway has been suggested resulting in the formation of 
compounds cis/trans-[OsX2(PP)2] in which the ligands display different reactivity. The size 
of the bidentate phosphine ligand determines the stereochemistry of the product complex. 
Reaction with short ligands such as dppm selectively yield the cis-[OsX2(PP)2] isomers. 
Whilst reaction with dppe and dppp under the same conditions gives the trans-[OsX2(PP)2] 
isomers. Steric bulkiness of the ligands influences the stereochemistry. The cis-[OsX2(PP)2] 
isomers are thermally stable with onset of decomposition at temperatures above 300 °C. In 
contrast, the trans-[OsX2(PP)2] isomers were found to be thermally less stable and found to 
decompose in the range 195 – 251 °C. 
v 
 
Microwave irradiation of [Os3(CO)12] in the presence of PPh3 in acetonitrile solution gave a 
mixture of disubstituted and trisubstituted phosphine cluster complexes which have been 
characterized by IR, Raman, 
1
H and 
31
P (where applicable) NMR spectroscopies. Variation of 
solvents influences substitution and give a mixture of monosubstituted and disubstituted 
phosphine cluster. 
Complexes of the type [OsX2(PP)2] exhibited both anticancer and antimicrobial activity. In 
some instances the activity was comparable to that of the reference drugs. The complexes 
cis,cis,trans-[OsX2(CO)2(PR3)2] and phosphine substituted derivatives of [Os3(CO)12] 
exhibited moderate antibacterial activity against Gram-negative bacterial strains and some 
fungal strains under study.  
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Chapter 1  
General introduction 
1.1 Bioinorganic chemistry 
 
Bioinorganic chemistry describes the role of inorganic substances in biological systems. This 
field encompasses a variety of disciplines including inorganic chemistry, biochemistry, 
molecular biology and medicine. Bioinorganic chemistry includes the study of both naturally 
occurring as well as synthetically introduced transition metals in medicine. Natural 
bioinorganic molecules include urease, an enzyme that catalyses the hydrolysis of urea to 
carbon monoxide and ammonia. Based on the X-ray crystal structure of this enzyme, the 
active centre contains two nickel ions.
1,2
 Metal ions play a vital role in various biological 
processes. Some of the complexes are particular on the type of metal and a specific oxidation 
state to execute the necessary catalytic function. 
 
Vitamin B12, also called cobalamin, and its coenzymes are naturally occuring cobalt-
containing compounds (Figure 1.1). Cobalamin is involved in the metabolism of every cell of 
the human body and plays a key role in processes such as fatty acid and amino acid 
metabolism.
3
 In many biological reactions metal ions are often found at the catalytic centre 
(active site) of enzymes. The metal ion can modify electron flow in a substrate or enzyme, 
thus effectively controlling an enzyme-catalyzed reaction. Many biological reactions involve 
water and examples of hydrolase enzymes are metallophosphatases and metalloproteinases 
which catalyse hydrolysis reactions. 
2 
 
 
 
 
Figure 1.1: Chemical structure of Vitamin B12 and related compounds. 
 
Inorganic compounds have been used in medicine, for treatment of various diseases and 
ailments for centuries. Introduction of metals into biological systems may be either for 
diagnostic or therapeutic purposes, although in many cases the two overlap. As early as 1910 
Paul Ehrlich reported on the use of metals in medicine. He introduced the organoarsenic 
compound 3-amino-4-hydroxyphenylarsenic(I) (Salvarsan) for treatment of syphilis, a 
disease caused by the spirochaete bacterium Treponema pallidum. This work demonstrated 
the relevance of the use of metals in medicine.
4
 Rosenberg’s discovery of the anticancer 
activity of Cisplatin,
5
 cis-[PtCl2(NH3)2] in 1965,  further fuelled interest in using transition 
metals in medicine. 
Bioinorganic complexes have found application in a wide variety of areas namely, 
photodynamic therapy, biocatalysis and pharmaceuticals.
6-8
  The work in this thesis involves 
the application of bioinorganic compounds as pharmaceuticals, particularly as anticancer and 
antimicrobial agents.  
3 
 
1.2 Bioinorganic compounds in pharmaceuticals  
 
Various bioinorganic complexes have been explored as pharmaceuticals that include 
antibacterial, antifungal and anticancer drugs. Metal complexes have properties that tend to 
offer advantages over organic molecules. The complexes diverse coordination numbers as 
well as coordination geometries offer novel mechanisms of action not available to organic 
compounds.  
1.2.1 Bioinorganic complexes as antibacterial agents 
 
Bioinorganic compounds have shown a lot of success in the area of antimicrobial drugs. The 
growing interest in inorganic compounds is owed to increasing resistance of the pathogens 
against organic drugs. The accidental discovery of Penicillin (Figure 1.2) by Alexander 
Fleming in 1928 marked the beginning of antimicrobial research, although clinical use of 
penicillin was only later reported in the 1940s.
9
 Within a few years of therapeutic use there 
were reports on resistance against these organic antibiotics.
10
 
    
 
 
Figure 1.2: Penicillin, with a -lactam antibiotic core structure, where R is a variable group. 
 
Meticillin, a -lactam antibiotic of the penicillin class, was introduced in 1959 to address 
penicillin-resistance. Again within a few years this -lactam suffered resistance against the 
Gram positive bacteria Staphylococcus aureus. Over the years this bacterial strain developed 
multiple-antibiotic resistance against several classes of antibiotics.
11
 Another class of 
4 
 
antibiotics such as gentamycin, erythromycin and neomycin were later shown to be 
susceptible to resistance. The Staphylococcus aureus bacterial strain was also reported to 
develop resistance against a fluoroquinoline antibiotic, ciprofloxacin.
12
 To combat the multi-
resistance of Staphylococcus aureus Vancomycin, a glycopeptides antibiotic that has been 
used for the past two decades. Staphylococcus aureus was also later reported to have 
developed resistance against this antibiotic.
13
 This shows that pathogens routinely develop 
resistance against purely organic antibiotics. Hence, there is a need to develop new antibiotics 
with novel modes of action to control virulence of multidrug resistant pathogens. 
 
Combination of an organic moiety and a metal is one of the strategies used in overcoming 
resistance. The metal can offer a novel mechanism of action not available for a purely organic 
molecule. A number of papers on the metal modification of organic structures have been 
reported in literature.
14-17
 The majority of these complexes were found to possess higher 
biological activity than the parent organic drug. An example includes the antimalarial 
candidate Ferroquine, a derivative of chloroquine (Scheme 1.1). Ferroquine has been reported 
to overcome chloroquine-resistance against Plasmodium falciparum (Dd2).
15
 
 
Scheme 1.1: Synthesis of Ferroquine. 
 
Similarly, the efficacy of the organic drug Pentamidine has decreased due to increased 
bacterial resistance. To try and overcome drug resistance the existing antimicrobial drug has 
been complexed with several different metal centres and activity evaluated against 
5 
 
Leishmania donovani DD8 promastigotes. Of these the organo-iridium derivative, Ir-(COT)-
pentamidine alizarin red (Figure 1.3), was found to have a higher therapeutic index than 
pentamidine against the parasitic disease leishmanias.
17
 
 
 
 
Figure 1.3: Chemical structure of Ir-(COT)pentamidine alizarin red. 
 
 
Multinuclearity have also shown to be an innovative strategy in improving biological activity 
with respect to the mononuclear compounds. This is attributed to increased stability, 
lipophilicity and/or solubility of the organometallic scaffolds. The work by Prof G. Smith and 
colleagues show the synthesis of dinuclear Ru(II) arene compounds complexed with aryl 
ether moieties (Scheme 1.2).
18,19
 Complexation  leads to enhanced synergistic biological 
effect. The ligands stabilize the metal framework and allow delivery of the intact complex to 
the pharmacological target. These complexes showed increased inhibitory effects against the 
human protozoal parasite compared to the dimer as well as the free ligand. 
 
 
Scheme 1.2: Dinuclear Ru(II) arene complex. 
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1.2.2 Bioinorganic complexes as antifungal agents 
 
The development of antifungal agents has failed to keep up with that of antibacterial agents. 
This is a consequence of the distinction between structures of the two organisms involved. 
Bacteria are prokaryotes and hence offer different structural and metabolic targets different 
from the host. In contrast, fungi are eukaryotes and as a result most agents toxic to fungi are 
also toxic to the host. In addition, because fungi generally are slow growing and often in 
multicellular forms, they are more difficult to quantify than bacteria. 
  
Regardless of these limitations, numerous advances have been made in developing new 
antifungal agents. Many antifungal agents that are currently in use are organic based and have 
limitations which include undesirable toxic effects. Continued use of these agents had led to 
development of drug resistance which leads to failure of the treatment. 
To overcome this resistance the organic molecules are modified by incorporating metal ions. 
Various metal containing antifungal agents have been prepared and the activity evaluated. 
The silver sulfadiazine, a coordination complex formed by reacting sulfadiazine with 
inorganic silver salt such as silver nitrate (Scheme 1.2)
20
, is an effective antifungal agent.  Its 
activity is owed to combination of both silver and the sulfadiazine. The silver ion is thought 
to bind to DNA of the organism and the sulphonamide interferes with metabolic pathway of 
the microbe. This compound is active against Candida albicans and Staphylococcus aureus 
strains. Silver sulfadiazine is used as a topical cream to prevent and treat infections among 
burned patients.
21
  
 
7 
 
 
 
Scheme 1.3: Preparation of silver sulfadiazine. 
 
Incorporation of metal ions into organic molecule has proved effective in antifungal agents. 
The Cu(II) and Au(I) complexes of clotrimazole and ketoconazole exhibited higher inhibitory 
activity than the parent compound against cultures of Trypanosama cruzi.
22
 The ruthenium 
clotrimazole complex also showed enhanced efficacy against Trypanosome cruzi relative to 
the ligand.
23
 Metal complexes containing a thiadiazine core have been demonstrated to 
possess antifungal properties. It is well established that the thiadiazine-thione moiety exhibits 
antifungal activity through the production of isothiocyanate and dithiocarbamic acids.
24
 
1.2.3 Bioinorganic complexes as anticancer agents 
 
Although the use of bioinorganic complexes is not limited to anticancer agents, it nonetheless 
represents the most intensely researched area of application. Examples of metal-based 
anticancer agents include the platinum compound Cisplatin and its derivatives as well as 
ruthenium and osmium arene complexes and also triosmium carbonyl cluster complexes. 
These complexes have shown different modes of activity. 
 
1.2.3.1 Cisplatin and related platinum compounds 
 
Cisplatin is a tetracoordinated platinum(II) complex, [Pt(NH3)2Cl2], which adopts a square 
planar geometry (Scheme 1.3, complex A). This bioinorganic complex is a leading anticancer 
agent and it is has been shown to derive its antitumour effect by interaction with DNA.
25,26
  It 
8 
 
was first synthesized in 1844 by Peyrone
27
 yet its anticancer activity was only discovered in 
the 1960s by Rosenberg and was approved for clinical use in 1978.
8
 
 
Cisplatin is administered intravenously. The high concentration of chloride in the blood 
prevents activation of the complex and it remains intact. Intracellular chloride concentration 
is less than extracellular levels.  In the cell the complex is activated with Pt(II)Cl bond 
cleavage.
28
  One of the two chlorido ligands, in a process called aquation, is cleaved. The lost 
chlorido ligand is substituted by an aqua ligand forming an active positively charged species 
[Pt(NH3)2Cl(H2O)]
+ 
(Scheme 1.3, complex B).
29
  The active species is then attracted to the 
negatively charged end of the DNA forming a platinum-DNA adduct (Scheme 1.3, complex 
D). Complex B, [Pt(NH3)2Cl(H2O)]
+
,
 
can further be hydrolysed, losing the second chlorido 
ligand (Scheme 1.3, complex C). The resulting complex reacts with an adjacent base forming 
a 1,2 intrastrand adduct with DNA (Scheme 1.3, complex E). This DNA-Cisplatin adduct can 
stimulate a variety of cellular responses, such as apoptosis and G2 cell cycle arrest.
30-33
 
Proteins responsible for replication of DNA cannot recognize the distorted double-strand 
helix and an attempt to repair the distorted DNA is made. If that is not achieved then a signal 
is released for apoptosis (programmed cell death) to take place. The activity of the platinum 
complex is owed to the direct interaction between the platinum(II) ion and DNA.
25,26
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Scheme 1.4: Hydrolysis of Cisplatin to form Cisplatin-DNA adduct (D and E).
34-35
 
 
Cisplatin has been clinically proven to combat different types of cancers including ovarian, 
lung, breast, prostate, esophageal, colon, testicular, head and neck as well melanoma 
cancer.
36
 Despite its success, Cisplatin suffers from limitations such as major side effects and 
drug resistance. Its success and drawbacks has stimulated the search for other platinum based 
compounds with the intention to improve on its therapeutic effect. Thousands analogues of 
Cisplatin were examined and only 13 of these analogues entered clinical trails. From these 
only a few, Carboplatin, Oxaliplatin, Nedaplatin, Heptaplatin and Lobaplatin, has been 
successfully used to treat solid tumours (Chart 1.1).
37
 
 
These platinum complexes suffer from severe side effects and this limits their use in the 
clinic. Use is also limited in many widespread tumours due to acquired or intrinsic resistance. 
These limitations inspired research on the design of new non-platinum compounds that are 
capable of widening the spectrum of activity and avoid platinum’s resistance.  
10 
 
 
Chart 1.1: Chemical structures of selected platinum drugs. 
 
1.2.3.2 Ruthenium complexes as anticancer agents  
Ruthenium complexes possess several favourable chemical properties that indicate it may be 
a suitable alternative transition metal for anticancer drug design. The non-platinum transition 
metal complexes offer the following advantages; i) Most Ru complexes adopt an octahedral 
geometry. Compared to the square planar geometry of the platinum complex, the octahedral 
complexes offer additional coordination sites; ii) Ru can occur in various oxidation states 2+, 
3+ and 4+ under physiological conditions; iii) The rate of ligand exchange is comparable to 
that of the platinum complexes or can be modified by introduction of ancillary ligands; iv) Ru 
has the ability to mimic Fe in binging to biomolecules, such as human serum albumin and 
transferring;
38
 v)  The Ru complexes have a different mechanism of action compared to the 
11 
 
Pt(II) complexes and this is a result of the difference in geometry between the complexes. Ru 
complexes predominately form inter-strand crosslinks with DNA as opposed to intra-strand 
cross links favoured by cisplatin.
39,40
 vi) The activation-by-reduction mechanism could also 
be responsible for the lower general toxicity of some ruthenium containing agents.
41,42
 The 
activation from Ru(III) to Ru(II) requires environments with low oxygen levels and these are 
obtained in hypoxic tumour cells, because of insufficient formation of new blood vessels and 
poor blood supply, as opposed to normal cells. vii) Ru complexes have a larger and different 
spectrum of activity.  
 
Amongst the Ru based pharmaceuticals showing anticancer activity Ru-arene complexes 
have attracted greatest interest. These complexes have shown stability, water-solubility and 
exhibit cytotoxicities against a range of cancer cell lines,
43
 including Cisplatin-resistant cell 
lines such as the human ovarian cancer cell line A2780.
44,45
 The Ru(II) arene complex [(6-p-
cymene)Ru(en)Cl)]
+
 exhibits both in vitro and in vivo activity comparable to that of  
Carboplatin.
46,47
 Similar to Cisplatin the Ru(II)-arene complexes selectively target specific 
DNA bases forming monofunctional DNA adducts.
47
 When bearing an extended arene ligand 
such as dihydroanthracene and biphenyl DNA intercalation is a possibility.  
 
Several ruthenium arene phosphaadamantane (RAPTA) complexes, another family of Ru(II)-
arene complexes, have been reported to exhibit cytotoxicity. In aqueous  solution the RAPTA 
complexes hydrolyses like Cisplatin, forming the activated aqua form of the RAPTA 
complex, [Ru(6-arene)Cl(H2O)(PTA)]
+ 
(Scheme 1.4).
48-50
  Some of  the RAPTA complexes 
have been shown to exhibit antimetastatic activity and others were proven to exert their 
activity by a DNA binding mechanism.
51,52
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Scheme 1.5 : Activation of Ru(II)Cl in RAPTA complexes. 
 
Ru(III)-arene complexes have also attracted interest because of their ability to fight against 
metastatic cancers
53
 and their high affinity to imine sites of biomolecules.
54,55
 Studies on 
these complexes show high selectivity for tumour cells and a general low toxicity. Ru(III)  
complexes currently in clinical trials, include NAMI-A (trans-
[tetrachloride(dimethylsulfoxide)(1H-imidzole) ruthenate(III)], KP1019 (Ru(III)-arene 
complexes; Indazolium trans-[tetrachloridobis(1H-indazole) ruthenate(III)] and  KP1339 
(sodium trans-[tetrachlorobis(1H-indazole) ruthenate(III)] (Chart 1.2). 
  
These Ru(III) complexes are structurally similar, however, they have a different spectrum of 
activity. NAMI-A has been found to inhibit the formation of cancer metastases while KP1019 
and KP1339 have shown activity against primary tumours by inducing apoptosis.
56,57
 Binding 
of the complex KP1019 to transferrin is thought to be an important step in the activity of this 
complex. The KP1019 complex initially accumulates in transferrin receptors in tumour cells, 
where it is reduced to a Ru(II) species.
58
 The reduced complex is then released from the 
protein in endosomes at a lower pH in the presence of biological chelators and binds to 
nucleotides and DNA triggering an apoptotic process.
59
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Chart 1.2: Structure of Ru(III) drugs. 
 
NAMI-A has been shown to exhibit anti-angiogenic and anti-invasive properties.
60
 Recent 
studies suggest that the “activation by reduction” hypothesis suggested by previous 
reseachers is not necessarily the reactivity pathway of the NAMI-A complex.
61
 This complex 
is generally labile at physiological pH and activation is postulated to occur by aquation.
62-64
 
The aqua ligand is very labile and can be easily lost through subsequent interaction with 
biomolecules. In addition, recent findings excludes DNA as the primary target for NAMI-A 
and suggests that proteins in tumour cells are likely to be the primary target for this complex.  
For many years focus has been directed to the preparation of complexes that could have 
direct interaction with DNA. However, recent studies on Ru arene complexes suggest that 
targeting other biomolecules such as proteins could prove to be more effective. These 
ruthenium compounds have demonstrated a novel mode of action. 
 
1.2.3.3 Osmium complexes as anticancer agents 
Osmium complexes are generally more inert towards hydrolysis compared to their ruthenium 
analogues. Hence, more often osmium complexes are found to be biologically inactive or 
have a lower activity than ruthenium complexes.
65,66
 However, there has been a growing 
14 
 
interest in the development of osmium complexes as anticancer agents. Some of the 
complexes under study showed promising antiproliferative activity (Chart 1.3).
67-69
 
 
 
Chart 1.3: Os(II) complexes which exhibit promising anticancer activity. 
 
Osmium offers a number of advantages over its lighter congener, ruthenium;  
i. It is a third-row transition metal and its complexes are more inert compared to second 
and first-row transition metal complexes. For example, the rate of ligand substitution 
of Pt(II) complexes are commonly ca. 5 orders of magnitude slower that those of 
Pd(II) and similarly Os(II) complexes are generally found to be more inert than their 
lighter congener Ru(II) complexes.
65,66,70
    
ii. Complexes of third row transition metals are generally more stable under 
physiological conditions,  
iii. Accessibility of various oxidation states,  
iv. From lower oxidation states stronger -back donation occurs.  
15 
 
These properties suggest that Os metal complexes are interesting candidates for further 
investigation as alternative for synthesis of new anticancer agents. 
 
Different approaches for the synthesis of osmium compounds with potential antitumour 
activity have been investigated. This gave birth to a range of osmium based compounds 
including mononuclear and multinuclear clusters with a variety of chemical and biological 
properties.
65,66,71,72
 The choice of the type of coordinated ligands and coordination geometry 
provides an ability to fine-tune the chemical reactivity of complexes, potentially allowing 
control of pharmacological properties, including cell uptake, distribution, DNA binding, 
metabolism and toxic side effects. 
 
a) Mononuclear osmium complexes 
Investigation of osmium transition metal as potential anticancer agents started with 
preparation of complexes that are structurally similar to Ru complexes of known anticancer 
activity. Osmium analogues of NAMI-A, KP1019 and KP1339 were prepared and the 
anticancer activity evaluated. These complexes showed a different mode of activity and were 
associated with very slow rate of hydrolysis compared to the Ru analogues. However, it was 
revealed that the rate of hydrolysis can be controlled by choice of ligands.
65,72
 The rate of 
hydrolysis of osmium analogue of NAMI-A was slow compared to the parent and related 
compounds,
73
  however, high cytotoxicity was observed. This suggested that hydrolysis is not 
an essential prerequisite for biological activity of this class of compounds.
74
 The osmium 
analogue of KP1019 also showed stability in aqueous media, and cytotoxicity similar to the 
ruthenium analogue.
75
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Various Os(II) analogues of RAPTA complexes have been prepared and their anticancer 
activity evaluated. Complex [Os(6-p-cymene)Cl2(pta)] (Chart 1.3) showed selectivity 
towards cancerous cells and exhibited cytotoxicity similar to the Ru analogue.
48
 However, the 
cationic derivative [Os(6-p-cymene)Cl2(pta-Me)]
+
 showed no selectivity and damaged both 
normal healthy and cancerous cells. Reactivity studies of osmium analogues of RAPTA 
compounds with biomolecules have been reported. A combination of theoretical and 
experimental data revealed that the osmium complexes bind to the DNA oligomer. Unlike 
Cisplatin, these complexes appear to be more specific in their cytotoxicity toward cancer 
cells relative to the healthy cells. This suggest a different binding mode is in operation or 
there is a different biological target for these class of complexes.
76
 
 
b) Osmium carbonyl clusters 
Organometallic osmium clusters have also shown potential as antitumour agents.
77,78
 The 
estrogen receptor (ER) –dependent MCF-7 and ER-independent MDA-MB-231 breast cancer 
cell lines were treated with a series of triosmium carbonyl cluster complexes of the type 
[Os3(CO)12-n(L)n] and their protonated analogues (L = nitriles, maltol, triphenylphosphine) 
and results show that the cytotoxicity of the complexes were strongly dependent on the type 
of coordinated ligands and solubility. Complexes containing labile ligands were significantly 
more active compared with complexes with nonlabile ligands.
79
 The [Os3(CO)10(CNMe)2] 
cluster has been reported to disrupt the normal functions of the cell by causing disruptions of 
the microtubule morphology.
79,80
 It is known that proper dynamics of microtubules are 
required for normal functioning and therefore, their hyperstabilization by Os clusters leads to 
cellular dysfunction and apoptosis. This can be explained by loss of the labile CNMe ligand 
and creation of a vacant coordination site at the metal centre allowing binding to 
biomolecules.  
17 
 
 
Cationic clusters showed enhanced activity compared to neutral analogues because of 
increased solubility and cell permeability. These clusters induce apoptosis and exhibit 
cytotoxicity in the micromolar range with selectivity for cancerous cells over normal 
epithelial cells. Studies show the mode of action of these complexes involve biotargets that 
are different from hormone receptors as the clusters were more potent against an ER-
independent cell line compared to ER-dependent cell line. At the molecular level the 
triosmium clusters interact with both intra and extracellular sulfhydryl groups.
79
 
 
Another approach to combat against cancer is targeting biomolecules other than DNA. The 
group of Colangelo studied the ability of a series of water-soluble quinoline-triosmium 
clusters [(H)Os3(CO)9(L)(3-
2
-(Q-H)], (where L = [P(C6H4SO3Na)3] or 
[P(OCH2CH2NMe3I)3] and Q = quinoline, 3-aminoquinoline, quinoxaline or phenanthridine) 
(Chart 1.3) to inhibit telomerase, a crucial enzyme for cancer progression.
77
 The quinoline 
substituent was selected because of its well-known biological properties, especially  
inhibiting enzymes.
81,82
 Among the clusters studied the negatively charged clusters (Chart 1.3 
complex F(i)-I(i) were able to inhibit telomerase activity in the cell-free biochemical assay. 
However,  these clusters were ineffective in vitro on Taq, a different DNA polymerase.
77
 This 
suggests that these clusters are selective for telomerase. 
 
The positively charged clusters (F(ii)-I(ii)) were found to be inactive and no further 
investigation was carried out on these clusters. These results suggest that the interaction of 
these clusters to telomerase is electrostatic. In fact, the telomerase is rich in positively 
charged amino acids, such as lysine and arginine and it was postulated that the negatively 
charged portion of the clusters interact with these amino acids.
77
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The group of Rosenberg studied the interaction of triosmium clusters with albumin.
83
 The 
water soluble clusters [Os3(CO)9(-
2
-Bz)(-H)L] (L = [P(OCH2CH2NMe3)3I3]; Bz =  
quinoxaline]
 
and its negatively charged
 
analog [Os3(CO)9(-
2
-Bz)(-H)L] (L = 
[P(C6H4SO3)3Na3]; Bz = phenanthridine, benzoquinoline, 3-amino quinoline)  have been 
prepared and evaluated. Results show that the negatively charged clusters bind more tightly 
to albumin compared to their positively charged analogues. It was hypothesised that this 
could result from electrostatic attraction towards the positively charged amino acid groups of 
albumin.
83
  
 
Osmium complexes show potential as new anticancer agents and further investigation is 
necessary. The reactivity of Os complexes is dependent on the coordinated ligand. The choice 
of the type of coordinated ligands and coordination geometry provides an ability to fine-tune 
the chemical reactivity of complexes, potentially allowing control of pharmacological 
properties, including cell uptake, distribution, DNA binding, metabolism and toxic side 
effects. 
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Chart 1.4: Triosmium clusters with potential inhibition of telomerase enzyme. 
1.3 Aims and objectives 
 
The overall aim of this project is to investigate aspects of the synthesis, characterization and 
structural features of osmium-halide complexes coordinated to different P-donor ligands. 
Furthermore, we will report here the biological activity, anticancer and antimicrobial, of 
selected complexes. 
Specific aims 
 Synthesis of osmium carbonyl complexes of the type [OsX2(CO)2(PR3)2] from stable 
osmium salts Y2[OsX6]
2-
 (Y = NH4, K; X = Cl, Br, I) using the method demonstrate 
by Hales and Irving (where PR3 =  triphenylphosphine (P(C6H5)3), 
benzyldiphenylphosphine (Ph2P(CH2C6H5)), tribenzylphosphine (P(CH2C6H5)3), 
tricyclohexylphosphine.  
20 
 
 Microwave-assisted preparation of coordination complexes of the type [OsX2(PP)2] 
from osmium salt Y2[OsX6]
2- 
(where PP = dppm, dppe, dppp, dppb).  
 Preparation of osmium carbonyl cluster complexes under pressurised CO gas and 
further substitution using microwave heating to produce substituted cluster complexes 
of the type Os3(CO)12-n(PR3)n (n = 1 – 3).  
 The change in phosphine and halide ligands will address important aspects that will 
be investigated. 
1. Effect of change in halide and phosphine ligand on the bioactivity of 
the complex. 
2. Thermal stability of complexes using TGA. 
3. The effect of monodentate ligands vs bidentate ligands on the 
reactivity and bioactivity of the complexes. 
The complexes studied have demonstrated application as catalysts, molecular electronic 
devices, and use in organic synthesis.
84-87
 In contrast, to the best of our knowledge the use of 
these complexes as pharmaceuticals has remained unexplored. It is thus of interest to 
investigate the possibility of using these complexes for anticancer and antimicrobial 
purposes. The scope of the study thus involved the synthesis and characterization of 
complexes of the type [OsX2(CO)2(PR3)2], [OsX2(PP)2],[Os3(CO)11(P-P)] and [Os3(CO)12-
n(PR3)n] (n = 1-3) and exploration of their application as anticancer and antimicrobial agents. 
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Chapter 2 
Os(II) dicarbonyl-dihalido-diphosphine 
complexes 
2.1 Background 
2.1.1 [OsX2(CO)2(PR3)2] complexes 
 
The chemistry of osmium containing complexes has been of interest for the past 60 years, 
mainly because of the wide range of chemical properties exhibited by these complexes.
1-5
 
These properties are directed by the coordinated ligands, structure and stereochemistry of the 
complex and the metal oxidation state. Heteroleptic metal(II) complexes of group 8 
containing at least one halide ligand, one CO group and P-donor ligands have been of interest 
as catalysts,
6,7
 some have shown photochemical properties
4,5,8
 and the group of Dharmaraj 
have discussed their potential application as therapeutics.
9
  
In addition to the various chemical properties offered by osmium complexes of the type 
[OsX2(CO)2(PR3)2], continued interest is also increased by their ease of accessibility and 
because these complexes are highly reactive they are increasingly being used as precursors 
for other Os(II) derivatives.
4
 Various methods can be used for preparation. 
2.1.2 Preparatory methods 
 
Various methods are known for preparation of complexes of the type [MX2(CO)2(PR3)2] 
(where M = Os, Ru; X = Cl, Br, I; PR3 = tertiary monophosphine). This includes 
carbonylation of Os(III) halides [MCl3] in alcohol media followed by coordination of 
appropriate phosphine ligand (Scheme 2.1, Eq. 1).
10
 This route is most effective with 
carbonylation of [RuCl3]. However, carbonylation of [OsCl3] is slow because of general poor 
solubility. For preparation of osmium derivatives the more soluble Os(IV) hexahalide salt, 
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[OsX6]
2-
,
 
 is used instead (Scheme 2.1, Eq. 2).
10
  Carbonylation of phosphine-substituted 
metal halides such as [MX2(PR3)3] (Scheme 2.1, Eq. 3)
11
 
  
Scheme 2.1: Preparation of [OsCl2(CO)2(PR3)2] via carbonylation. 
 
These complexes can also be prepared via ligand substitution. The appropriate ligand 
replaces coordinated CO ligand in the neutral metal carbonyl halides complex [Os(-
Cl)2(CO)3]2,  breaking halide bridges (Scheme 2.2, Eq. 4).
12
 Interaction of appropriate ligand 
with polymeric metal carbonyl halide (Scheme 2.2, Eq. 5).
13
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Scheme 2.2: Preparation of [OsX2(CO)2(PR3)2] via ligand substitution. 
2.1.3 Focus of this study 
 
In this section of the study a series of [MX2(CO)2(PR3)2] complexes (where M = Os; PR3 = 
tertiary phosphine and X = Cl, Br, I) were synthesised. A lot of research which focused on 
the preparation of these complexes has been reported. However, none of the work 
investigated the effect of varying the R group of the tertiary phosphine and halide ligands on 
the spectroscopic data and biological activity of these complexes. 
This class of compounds is of interest because they contain potentially labile ligands. It is this 
cis-configuration of the labile ligands (Cl, Br, I) in this type of complex where application in 
pharmaceuticals, particularly anticancer agents, can be found. Chart 2.1 is a representative of 
the 9 complexes synthesised in this chapter. 
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Chart 2.1: Os(II) carbonyl complexes synthesized. 
2.2 Synthesis  
 
Collman’s approach10 was employed in the synthesis of the desired osmium carbonyl 
complexes, [OsX2(CO)2(PR3)2] (Scheme 2.3). 
Scheme 2.3: Synthesis of complex 1a-c, 2a-4b. 
Carbonylation of the hexahalido osmate complex, [OsX6]
2-
, is accomplished by use of 2-
methoxyethanol, at 140 °C for 48 h under pressurised CO gas. Upon carbonylation the two 
carbonyl ligands take up mutually cis positions trans to the weak -accepting and -donating 
halide ligands. Ligands trans to each other use the same orbitals on the metal for bonding. 
Thus, if one ligand is a strong donor, the ligand trans to it cannot donate electrons to the 
metal resulting in a weaker interaction with the metal. In this cis-position the CO ligands 
have a better interaction with the low-spin d
6
 metal ion. Hence, cis-CO coordination is 
preferred. The cis-CO complex reacts with the PR3 under refluxing conditions. In contrast to 
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carbonyls, phosphines are weaker -acids and are forced to take mutually trans positions. 
Because of the bulkiness of the this ligand these positions are also sterically favoured. 
An attempt to prepare the iodine compounds of  PPh2(CH2C6H5), P(CH2C6H5)3 and P(C6H11)3 
was made however, that was without success. Carbonylation of the osmium salt K2OsI6 was 
achieved which was characterized by IR spectroscopy. Coordination of the phosphine ligands 
difficult to achieve which made it difficult to prepare the desired [OsI2(CO)2(PR3)2] (PR3 = 
PPh2(CH2C6H5), P(CH2C6H5)3, P(C6H11)3). Failure to prepare these complexes could result 
from formation of  trans,cis,cis-[OsI2(CO)4]] instead of the required cis,trans,cis[OsI4(CO)2] 
upon carbonylation. These two would result in similar IR spectra. Hence, coordination of 
phosphine ligands will be difficult for the former complex. 
The desired cis,cis,trans-[OsX2(CO)2(PR3)2] complexes were formed as solids in yields 
ranging from 31 – 92%.   The resulting products were characterized spectroscopically using 
FT-IR, NMR (
1
H, 
13
C{H}, 
31
P{H}), Raman spectroscopy, elemental analysis and X-ray 
crystallography.  
2.3 Results and discussions 
 
The Os(II) carbonyl-halide-phosphine complexes 1a-c, 2a-4b were characterized in solution 
using NMR spectroscopy and solid state FT-IR, Raman as well as molecular crystal structure 
determinations for selected complexes. 
2.3.1 Infra-red spectroscopy 
 
The stretching vibrational frequencies, CO), of the coordinated CO ligands in complexes 1a-
c, 2a-4b are given in Table 2.1. The infrared spectra of complexes (1a-c, 2a-4b) show two 
bands in the CO) region, characteristic of mutually cis carbonyl ligands.
12-14
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The CO vibration for free CO occurs at 2143 cm-1. The shift in the CO stretching frequency 
of the coordinated CO is influenced by electron density donation from the metal to the carbon 
monoxide ligand via backbonding. A decrease in the frequency of CO bands is characteristic 
of an increase in backbonding. The MCO bond strengthens and shortens and in turn the 
CO bond is weakened and becomes longer. 
The cis,cis,trans-[OsX2(CO)2(PR3)2] complexes show a significant change in CO) with 
change in PR3. This results from the difference in the -donating ability of the PR3 ligands 
(Figure 2.1).  
Table 2.1: IR data in the carbonyl region of complex 1a-c, 2a-4b. 
Complex   Carbonyl stretching frequencies (CO, cm
-1
)
a
 for 
cis,cis,trans-[OsBr2(CO)2(PR3)2] complexes 
 PR3 X           B2 (Asymmetric stretch) A1 (Symmetric stretch) 
1a P(C6H5)3  Cl          2043 1960 
1b  Br            2042 1960 
1c   I           2033 1962 
2a Ph2P(CH2C6H5)  Cl         2036 1962 
2b   Br         2040 1970 
3a P(CH2C6H5)3  Cl         2034 1960 
3b   Br           2023 1953 
4a P(C6H11)3  Cl        2010 1933 
4b   Br          2012 1939 
a
Measured in solid-state.  
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The CO) decreases in the order P(C6H5)3  Ph2P(CH2C6H5)  P(CH2C6H5)3  P(C6H11)3. This 
trend is consistent with a decrease in the -donor and an increase in -acceptor ability of 
these ligands (Table 2.1). 
 
Figure 2.1: Tertiary PR3 ligands showing the trend of decreasing -donor and increasing -
acceptor ability. 
 
The CO stretching frequencies of the complexes show an decrease in the order Cl  Br  I for 
the asymmetric stretch in the case where the halides are changed and ligand PR3 remains the 
same.
15
 Although a negligible change is observed going from Cl to Br, which may result from 
the small difference in electronegativity between the two atoms.  However, a significant 
decrease in the CO stretching frequency is observed moving from Br to I. The inductive 
effect of the halide is considered to decrease along this series and the -bonding capabilities 
to increase.
16
  The decrease in inductive power going from Cl to I leads to greater electron 
density on the metal which in turn redistributs the electron density in the M-CO -system. 
This leads to an decrease in the stretching frequency. If -bonding effect was the contributing 
effect then the CO stretching frequency would be expected to increase.
13
 In this case the 
inductive power is the important contributing factor. Unfortunately, there is no clear trend in 
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the symmetric stretch, although for complex [OsX2(CO)2(PPh3)2] (where X = Cl, Br, I) the 
symmetric stretch remains relatively constant. 
The IR spectrum of complex 1b is given in Figure 2.2, two bands were observed. The point 
group/symmetry type of the complexes assists in predicting the number of carbonyl stretching 
frequencies in the IR spectrum. Two bands are predicted as shown by the IR spectrum. The 
two bands: symmetric A1 and asymmetric B2 modes corresponds to C2v symmetry (Figure 
2.3). 
      
Figure 2.2: IR spectrum of complex cis,cis,trans-[OsBr2(CO)2{P(C6H5)3}2], 1b  in carbonyl 
region.
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Figure 2.3: IR-active normal modes observed for cis,cis,trans-[OsX2(CO)2(PR3)2] 
complexes. 
 
2.3.2 Raman spectroscopy 
 
The Raman spectroscopy data of complex 1a-c and 2a-4b are given in Table 2.2. Two CO 
stretching vibrations are observed in the Raman spectra. The data obtained in this study is 
comparable to data obtained in IR spectroscopic studies. The far-IR region of the spectrum of 
each complex shows two bands attributed to the symmetric and asymmetric vibrations of the 
cis-OsX2 fragment (Figure 2.4).  
The Raman spectrum of cis,cis,trans-[OsBr2(CO)2{P(CH2C6H5)3}2], 3b,  is shown in Figure 
2.4. Two intense bands assigned to carbonyl stretches are observed in the 1800 – 2200 cm-1 
region. Two bands
 
due to OsBr at 216 and 189 cm-1 are observed suggesting the bromide 
ligands are mutually cis. Data given in Table 2.2 suggests that this is the case for all of the 
complexes reported. The OsX stretching modes are observed for OsCl between 305 and 
312 cm
-1
, OsBr between 210 and 221 and OsI between 157 and 174 cm-1. 
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Table 2.2: (CO) and far-IR spectra (400 – 100 cm-1) of 1a-c and 2a-4b  complexes. 
Complexes   Carbonyl stretching frequencies (CO, cm
-1
)
a
 
and far-IR for cis,cis,trans-
[OsBr2(CO)2(PR3)2] complexes 
 PR3 X CO) 
Asym, Sym 
Os-X 
Asym, Sym 
1a P(C6H5)3 Cl 2042, 1959 308, 284 
1b  Br 2041, 1962 229, 210 
1c  I 2036, 1973 174, 157 
2a Ph2P(CH2C6H5) Cl 2045, 1978 312, 285 
2b  Br 2041, 1978 210, 190 
3a P(CH2C6H5)3 Cl 2035, 1978 311, 305 
3b  Br 2026, 1955 216, 189 
4a P(C6H11)3 Cl 2012, 1919 305, 224 
4b  Br 2012, 1941 221, 189 
a
Measured in solid-state.  
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Figure 2.4: Raman spectrum of 3b illustrating the carbonyl signals and OsBr stretching 
modes. 
 
2.3.3 
1
H NMR spectroscopy 
 
The NMR data for complexes 1a – c, 2a - 4b are given in Table 2.3. The NMR spectra show 
resonances characteristic of a coordinated PR3 ligand. Coordination of the PR3 ligand to the 
metal centre has a marked influence on the PR3 proton chemical shifts. Comparison of the 
chemical shifts of the uncoordinated PR3 ligands and that of the coordinated show a 
downfield shift (Table 2.3). 
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Table 2.3: 
1
H NMR data of complex 1a – c, 2a - 4b and free ligands. Spectra recorded in 
CDCl3. 
Complexes  (1H NMR) ppm Coupling constant, 
J  (Hz) 
Assignment 
(Proton) 
Free P(C6H5)3 7.40 – 7.46 (m)  H-aromatic 
1a 7.87 (dt) 
7.40 (dd) 
9.4, 5.3 
 3.7, 2.3 
H-aromatic 
1b 7.89 (ddd)  
7.48 – 7.30 (m)  
9.8, 6.6, 3.4 H-aromatic 
1c 7.90 (dddd) 
7.45 – 7.28 (m) 
9.6, 3.7, 2.5, 1.3 H-aromatic 
Free Ph2P(CH2C6H5) 7.80 - 7.65(m) 
7.62 - 7.31(m) 
7.29 - 7.03(m) 
3.45(s) 
- 
- 
- 
- 
H-aromatic 
H-aromatic 
H-aromatic 
CH2-benzyl 
2a 7.75 – 7.57 (m) 
7.49 – 7.18 (m) 
6.93 (dt) 
6.60 (d) 
4.41 (t) 
- 
- 
25.2, 7.2 
7.1 
4.4 
H-aromatic 
H-aromatic 
H-aromatic 
H-aromatic 
CH2 benzyl 
2b 7.69 (ddd) 
7.47 – 7.21 (m) 
6.96 (dt) 
6.60 (d) 
4.56 (t) 
10.3, 6.1, 1.9 
- 
25.9, 7.2 
7.2 
4.3 
H-aromatic 
H-aromatic 
H-aromatic 
H-aromatic 
CH2 benzyl 
Free P(CH2C6H5)3 7.94 - 7.84 (m) 
3.26 - 2.87 (m) 
- 
- 
H-aromatic 
CH2 benzyl 
3a 7.46 – 7.15 (m) 
7.16 – 6.98 (m) 
3.61 (t) 
- 
- 
3.8 
H-aromatic 
H-aromatic 
CH2 benzyl 
3b 7.23 (t) 
7.08 – 6.93 (m) 
3.72 (t) 
3.3 
 
3.8 
H-aromatic 
H-aromatic 
CH2 benzyl 
Free P(C6H11)3 2.04 – 1.03 (m) 
1.24 (d) 
- 
7.7 
H- alkyl 
H-alkyl 
4a 2.72 – 2.47 (m) 
2.14 (d) 
1.77 (d) 
1.66 – 1.32 (m) 
1.29 (d) 
- 
11.7 
35.0 
- 
7.4 
H- alkyl 
H-alkyl 
H- alkyl 
H-alkyl 
H-alkyl 
4b 2.82 – 2.51 (m) 
2.19 (d) 
1.83 (s) 
1.72 (s) 
1.68 – 1.34 (m) 
- 
11.8 
- 
- 
- 
 
H- alkyl 
H-alkyl 
H- alkyl 
H-alkyl 
H-alkyl 
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The shift in resonance is a consequence of the different electronegativity of the substituents 
on the phosphorus atom. This has also been observed for related complexes.
17
  
The multiplets in the aromatic region with relative intensities 2:3 were present in all spectra 
of complexes [OsX2(CO)2{P(C6H5)3}2] (X = Cl (1a), Br (1b), I (1c)) and assigned to the 
aromatic protons of triphenylphosphine (Table 2.3). The large downfield shift of the aromatic 
protons is a consequence of coordination to the osmium centre. The chemical shift of the 
aromatic protons was not found to be influenced by the variation of the halide ligands. This is 
shown by the minor difference in the chemical shift values of the aromatic protons in 
complex 1a (7.87 ppm, 7.40 ppm), 1b (7.89 ppm, 7.48 – 7.30 ppm) (Figure 2.5) and 1c (7.90 
ppm, 7.45 – 7.28 ppm) for the chlorido, bromido and iodido complexes, respectively. 
 
  
Figure 2.5: 
1
H NMR spectrum of complex 1b in CDCl3. 
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The 
1
H NMR spectrum of 2a showed resonances at 7.75 – 7.18, 6.93 – 6.60 and 4.41 ppm 
for phenyl, benzyl and methylene protons, respectively (Figure 2.6). A triplet assigned to 
methylene protons is observed in both complexes containing Ph2P(CH2C6H5) at  4.56 (J(PH) 
= 4.3 Hz) and at  4.41 (J(PH) = 4.4 Hz ) ppm for the bromido (2b) and the chlorido (2a) 
complexes, respectively. The magnitude of these coupling constant suggests that the protons 
are coupled to phosphorus in a similar manner and that the structures of the two complexes 
are similar. 
 
Figure 2.6:  
1
H NMR spectrum of 2a in CDCl3 
  
Complex 3a exhibits the aromatic proton signals between  7.46 – 6.98 ppm as multiplets. 
The methylene protons are seen at 3.61 ppm as a triplet (Figure 2.7). The triplet results 
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from coupling to the the phosphorus atom. Both complexes show triplet resonances at  3.72 
(J(HP) = 3.8 Hz) and 3.61 (J(HP) = 3.8 Hz) for 3b and 3a respectively. 
 
Figure 2.7:  
1
H NMR spectrum of 3a in CDCl3. 
 
Five broad multiplets are observed in the 
1
H NMR spectra of complex 4a assigned to the 
aliphatic protons (Figure 2.8). Complex 4b show similar resonance and data is given in Table 
2.3. 
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Figure 2.8: 
1
H NMR spectrum of 4a. 
2.3.4 
13
C{H} NMR spectroscopy 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
The 
13
C NMR data for complexes 1a – c and 2a – 4b are reported in Table 2.4. Figure 2.9 
shows the 
13
C NMR spectrum of complex 3b. The complex exhibits resonances assigned to 
the coordinated PR3 ligands and resonances further downfield assigned to the geometrically 
equivalent carbonyl ligands with a pattern that is similar to that observed for the 
corresponding metal(II) carbonyl dihalido complexes containing phosphine ligands.
15,18
  The 
triplet pattern of the resonance downfield is due to coupling of the carbon of CO group to the 
two phosphorus nuclei.
19
 This supports data obtained from IR spectroscopy that these 
carbonyl groups are cis coordinated. Variation of X with PR3 constant shows an upfield shift, 
which follows the trend I  Br  Cl. This is in agreement with inductive effect of halide 
ligands.
15
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Table 2.4: Selected 
13
C NMR data for 1a-c and 2a-4b complexes. 
Complex Chemical shift (CO, ppm)
a
 Coupling constant (J, Hz) 
1a 172.88 (t) 7.1 
1b 171.69 (t) 7.1 
1c 169.93 (t) 6.8 
2a 172.52 (t) 6.8 
2b 171.45 (t) 6.8 
3a 172.52 (t) 7.1 
3b 171.74 (t) 7.1 
4a 176.91 (t) 7.3 
4b 175.66 (t) 7.3 
a
Spectra recorded in CDCl3 
 
 
Figure 2.9: 
13
C{H} NMR spectrum of 3b in CDCl3. 
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2.3.5 
31
P{H} NMR spectroscopy 
 
The 
31
P NMR data of 1a – c and 2a – 4b are given in Table 2.5. These complexes exhibit a 
single intense peak assigned to two chemically and magnetically equivalent phosphorus 
nuclei. This further confirms the trans coordination of the phosphine groups. On either side 
of the 
31
P peak are two pairs of satellite peaks. The phosphorus nuclei, 
31
P, couples to the spin 
active nuclei (
13
C and 
187
Os), each resulting in a pair of satellites (Figure 2.10). 
Table 2.5: 
31
P NMR chemical shift of free ligands and 1a –c and 2a – 4b complexes. 
Complexes Chemical shift (, ppm)a 
Free P(C6H5)3 -5.28 
1a -10.21 
1b -17.16 
1c -28.44 
Free Ph2P(CH2C6H5) -9.77 
2a -3.80 
2b -11.06 
Free P(CH2C6H5)3 41.08 
3a -12.97 
3b -23.17 
Free P(C6H11)3 50.41 
4a -2.63 
4b -10.57 
a
Spectra recorded in CDCl3 
Data in the Table 2.5 shows that (31P) chemical shift of the uncoordinated phosphine ligand 
show a downfiled shift with an increase in the phosphine cone angle. Upon coordination to 
osmium centre the 
31
P NMR resonance is shifted upfield except for complex 2a, shown in 
spectra (Figure 2.11). Electronegativity of the substituents, R, on the phosphorus is also an 
important contributor to the (31P) chemical shift. Upon coordination electron density is 
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donated from phosphorus to the metal centre and subsequently the increased electron density 
at the metal promotes -back donation from the metal to the PR *-orbital result in the 
upfield shift observed.
20
 
The P) chemical shift is influenced by the change in cone angle of the PR3 ligand. The 
P) for osmium-bromide complexes, [OsBr2(CO)2(PR3)2] (PR3 = P(C6H5)3, 
Ph2P(CH2C6H5), P(CH2C6H5)3,  P(C6H11)3) is related to the cone angle of the phosphine 
ligand, larger cone angles exhibit P resonance downfield.  
  
 
Figure 2.10: 
31
P{H} NMR spectrum of 2b showing 
187
Os and 
13
C satellites. 
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Figure 2.11: 
31
P{H} NMR comparing chemical shift of free ligand to the complex 1a, 1b and 
1c. 
Variation of the halide, with PR3 unchanged, shows an upfield shift following this trend Cl  
Br  I.   This trend agrees with the -electron withdrawing effect of halides.12 The chemical 
shifts have been measured at (31P) = -10.21; -17.16; -28.44 ppm for X = Cl, Br and I, 
respectively. It is clear that inductive power of the halide ligands is the operating effect in 
these complexes.  
2.3.6 Thermo gravimetrical analysis (TGA)  
 
Thermal decomposition of the complexes was studied and found to be a two-stage process for 
complex 1a-c and 2a-3b, which can be directly related to the loss of ligands. The studies 
were carried out in the 100 – 1300 °C temperature range under nitrogen gas at a heating rate 
of 10 °C/min. The first stage is associated with loss of the halide ligands and CO groups. The 
second stage is characterized by release of phosphine ligands (Figure 2.12). The 
triphenylphosphine complexes 1a, 1b and 1c are stable to just above 250 °C. Data show that 
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1a is the most stable with onset of decomposition at 288 °C compared to 251 and 277 °C for 
1b and 1c, respectively.  
The onset of decomposition is 329 and 235 °C for 2a and 2b, respectively. Similar to 
complexes discussed above the initial stage of weight loss is associated with loss of the 
halides and CO groups. With the loss of benzyldiphenylphosphine ligands occurring in 
second stage. Similarly for complex 3a and 3b, the PR3 ligands are lost in the second stage. 
These complexes are stable for up until 336 and 345 °C, respectively.  
Interestingly, the tricyclohexylphosphine complexes, 4a and 4b totally decompose in a one 
step (Figure 2.13). Complex 4a on set of decomposition is at 305 °C, whilst 4b decomposes 
at a slightly higher temperature, 363 °C  
 
Figure 2.12: Thermogram of 3a showing two-step decomposition. 
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Figure 2.13: Thermogram  of 4a showing single-step decomposition. 
 
2.3.7 Crystallographic studies 
 
To confirm the structure of the complexes X-ray crystallography studies were conducted on 
selected complexes. The crystal data and experimental parameters are given in Table 2.6. 
Crystals of 2b, 3b and 4b suitable for X-ray diffraction were grown from dichloromethane 
(3b) and from chloroform solutions (2b and 4b), by slow evaporation of the solvent obtaining 
colourless/clear crystals of good quality. The geometric structures are represented by ORTEP 
plots in Figures 2.14 - 2.16. The atom numbering system used for the structural data is also 
included on the plots.  Complexes 2b and 3b were found to crystallize in the monoclinic and 
4b in the triclinic crystal system with P21/c, C2/c and P-1 space groups respectively. The 
complexes have pseudo-octahedral geometry. The osmium(II) is coordinated by two mutually 
trans phosphines in the axial positions, with the two bromines  and two carbonyl groups in 
equatorial in mutual cis positions (Figure 2.14 - 2.16).  This confirms data obtained from 
spectroscopic studies. Selected bond lengths (Å) and angles (°) for 2b – 4b are given in Table 
2.7.  
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Table 2.6: X-ray crystal data collection, solution and refinement details for 2b, 3b and 4b. 
            2b            3b             4b 
Formula C40H34Br2O2OsP2 C44H24Br2O2OsP2 C39H68Br2O2OsP2 
Molecular weight 958.63 1014.74 1051.79 
Crystal size 0.467  0.35  0.24 0.46  0.35  0.16 0.67  0.42  0.21 
Temperature(K) 173(2)  173(2)  173(2)  
Crystal system Monoclinic Monoclinic Triclinic 
Space group P21/c C2/c P-1 
a(Å) 11.4710(7) 23.3375(14)  10.4091 (2)  
b(Å) 18.6816(10) 18.3044(10)  10.6868(2)  
c(Å) 17.6815(10) 9.4310(10)  21.3533(4)  
(°) 90  90  84.6580(10)  
(°) 104.530(2)  98.962(2)  89.7640(10)  
(°) 90  90  64.9180(10)  
V(Å
3
) 3667.9(4) 3979.5(4) 2140.36(7) 
Z 4 4 2 
Dcalc (Mg/m
3
) 1.736 1.694 1.632 
F(000) 1864 1992 1056 
/mm-1 5.776 5.329 5.077 
Reflections 
collected 
99188 42003 88129 
Independent 
reflections 
8842 4818 10330 
Rint 0.0858 0.0707 0.0974 
Restrain/ 
parameters 
0/424 0/231 0/433 
Final R indices [I 
 2 sigma (I)] 
 
R1 = 0.0226 
wR2 = 0.0524 
R1 = 0.032 
wR2 = 0.0872 
R1 = 0.0289 
wR2 = 0.0716 
R indices (all data) R1 = 0.0284 
wR2 = 0.0552 
R1 = 0.0351 
wR2 = 0.0872 
R1 = 0.0316 
wR2 = 0.0724 
Goodness fit on F
2
 1.045 1.028 1.127 
Largest diff. peak 
and hole 
0.724 and -2.271 e. Å
-
3
 
6.693 and -1774 e. Å
-3
 2.029 and -2.271 e. 
Å
-3
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Table 2.7: Selected bond lengths (Å) and angles (°) with estimated standard deviations in 
paranthese for 2b, 3b and 4b. 
 2b 3b 4b 
Bond lengths    
OsBr(1) 
OsBr(2) 
2.578 
2.585 
2.579(5) 
2.579(5) 
2.596(3) 
2.582(3) 
OsC 1.873 
1.871 
1.866(5) 
1.866(4) 
1.880(3) 
1.867(3) 
OsP(1) 
OsP(2) 
2.407 
2.412 
2.413(9) 
2.413(9) 
2.487(7) 
2.486(8) 
CO 1.139 
1.136 
1.134(6) 1.140(4) 
1.125(4) 
Bond angles    
Br(1)OsBr(2) 89.07 91.43(3) 89.596(11) 
P(2)OsBr(1) 
P(2)OsBr(2) 
88.40 
88.54 
83.98(2) 
89.66(2) 
85.985(19) 
90.08(2) 
OsCO 177.95 
177.91 
177.3(4) 174.6(3) 
176.0(3) 
P(1)OsP(2) 175.42 170.90(4) 173.57(2) 
     
 
The complexes have approximately C2v symmetry and are isostructural with each other and 
the related osmium bromide [OsBr2(CO)2{P(C6H5)3}2] complex.
2,21
  The metal-bromide bond 
lengths in complex 2b, 3b and 4b (Table 2.7) are similar to other crystallographically 
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characterized Ru(II)- and Os(II) carbonyl bromide complexes, [RuBr2(CO)2{P(C6H5)3}2], 
RuBr(1) = 2.5940(6) Å, RuBr(2) = 2.5927(6) Å;22 [OsBr2(CO)2{P(C6H5)3}2], OsBr(1) = 
2.535(19) Å, OsBr(2) = 2.522(2) Å.2,21 In these complexes the bromide ligand are similarly 
trans to the CO group. The osmium-phosphorus bond lengths of complex 2b (2.410 Å 
(mean)) and 3b (2.413(9) Å) are comparable to other d
6
 transition metal complexes.
2,12,14,21-23
  
However, 4b (2.489(8) Å) has a slightly longer OsP bond length in contrast to other related 
d
6
 transition metal complexes. The longer OsP is expected since tricyclohexylphosphine has 
a larger cone angle and is sterically demanding compared to the other phosphines. Thus, the 
phosphines with smaller cone angle have shorter MP bond length.24  
The OsC bond lengths for complexes 2b, 3b and 4b are slightly longer than those observed 
for analogous Ru(II) complexes
14,23
 but comparable to other Os(II) complexes.
2,12,21
 The 
OsCO bond lengths are similar to those complexes containing CO groups that are trans to 
halides.
22,12,14
 The CO bond length in complexes 2b, 3b and 4b are different. Complex 4b 
has a longer CO bond, the tricyclohexyl phosphine ligand in this complex is a better -
donor than the benzyldiphenylphosphine and tribenzylphosphine, which means greater 
backbonding in 4b shown by longer CO bond distance, which correlates to difference in CO 
stretching frequency in FT-IR spectroscopy [2040 and 1970 cm
-1
 for 2b; 2023 and 1953 cm
-1
 
for 3b; 2012 and 1939 cm
-1
 for 4b]. 
The OsCO bond angles of the complexes under study are distorted slightly from linearity 
with angles less than 180°. OsCO = 177. 95°(2b); 177.3° (3b); 175.3° (mean) (4b). The 
bending is a result of conversion of a CO to a CO (Csp to Csp2 hybridization) caused by 
backbonding. As it is shown by data the complex with more backbonding is bent more.
25
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The POsP angle changes as the PR3 ligand is changed. In these complexes the PR3 ligand 
are inclined towards the bromine atoms, this is shown by the POsP angle being less than 
180° [170.90(4)° (3b); 173.67(2) °(4b); 175.42° (2b). The orientation of the PR3 ligand also 
differs. The P(C6H11)3 ligands in complex 4b (Figure 2.16) are staggered with respect to one 
another and  PR3 ligands are eclipsed in 2b and 3b (Figure 2.14 and Figure 2.15 
respectively).  
Short intramolecular interactions between hydrogen atoms of the PR3 ligands and bromides 
are observed in all complexes. Complex 2b show non-bonding intramolecular H
.....
Br 
distances [between H(4)
.....
Br(1) at 2.776 Å, H(23)
.....
Br(1) at 2.867 Å, H(34A)
.....
Br(1) 2.917 Å 
and H(15B)
.....
Br(1) 3.062Å] (Figure 2.13), all except one interactions are shorter than Van 
der Waals radii of hydrogen and bromine [rvdw(H) = 1.20, rvdw(Br) = 1.85 Å].
26
 Similary for 
complex 3b two short H
......
Br distances are observed between H(10)
.....
Br(3) at 2.695 Å, and 
between H(2)
.....
Br(3) at 2.866 Å (Figure 2.15). In the absence of strong interactions such as 
C=O
.....
HC, this weak Br.....H interactions are significant for crystal packing. In complex 4b 
short nonbonding intramolecular interactions are observed between Br(1)
.....
H(18B) at 2.891 
Å, Br(1)
.....
H(43B) at 2.720 Å, Br(2)
.....
H(34B) at 2.815 Å, Br(2)
.....
H(38B) at 2.784 Å and 
O(2)
.....
H(8B) at 2.984Å. In addition, stronger C=O
.....
HC interactions are also observed 
between O(1)
.....
H(9B) 2.423 and O(2)
.....
H(6B) 2.448 Å. O(2) is involved in both weak and 
strong interactions which may account for variation in OsC and CO bond lengths observed 
in the complex. Complex 4b was obtained as a solvate with a molecule of dicloromethane 
cocrystallized with the metal complex. 
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Figure 2.14: Thermal ellipsoid plot (50% probability level) of [OsBr2(CO)2{Ph2P 
(CH2C6H5)}2] (2b). 
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Figure 2.15: Thermal ellipsoid plot (50% probability level) of [OsBr2(CO)2{P(CH2C6H5)3}2] 
(3b). 
 
55 
 
 
Figure 2.16: Thermal ellipsoid plot (50% probability level) of 
[OsBr2(CO)2{P(C6H11)3}2]
.
CH2Cl2 (4b). 
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2.4  Conclusions 
 
Complexes of the type [OsX2(CO)2(PR3)2] (where X = Cl, Br, I; PR3 = P(C6H5)3, 
Ph2P(CH2C6H5), P(CH2C6H5)3, P(C6H11)3) can easily be prepared using Collman’s method of 
preparation, which involves the reductive carbonylation of Y2[OsX6]
2-
 (Y= NH4 or K; X = Cl, 
Br, I) with subsequent addition of appropriate phosphine ligand, PR3, to produce the 
respective complexes. This is a convenient route for synthesis of cis,cis,trans-configuration 
of these type of complexes. Vibrational spectroscopic data shows that(CO) varies in a 
systematic way with change in X and PR3. The carbonyl stretching frequency decreases with 
increasing -acceptor ability of PR3 ligand. Whilst v(CO) decreases in the order Cl  Br  I, 
which is constistent with the inductive power of the halide ligands.  
Some discrepancies with change in PR3 were observed in 
31
P NMR data. Explained by the 
difference in the -acceptor capabilities of the phosphine ligands and the size of the cone 
angle. A downfield chemical shift in the 
31
P{H} NMR spectrum correlates with an increase in 
cone angle.  
Thermogravimetrical analysis shows a two-stage decomposition process for complexes 1a-c, 
2a-3b and one-step for complexes 4a and 4b. The first stage is associated with loss of halides 
and CO groups. The second stage of decomposition correlates with loss of the phosphine 
ligands. All complexes are stable until temperatures above 190.00 °C.  
X-ray crystallographic data further confirmed the stereochemistry of compounds as  
cis,cis,trans-[OsBr2(CO)2{Ph2P(CH2C6H5)] 2b, cis,cis,trans-[OsBr2(CO)2{P(CH2C6H5)3}] 3b 
and cis,cis,trans-[OsBr2(CO)2{P(C6H11)3}] 4b complexes as suggested by other spectroscopic 
studies. 
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Chapter 3 
Microwave-assisted synthesis of Os(II) halido 
diphosphine complexes 
3.1 Background 
3.1.1 Microwave-promoted synthetic technique 
 
Microwave heating involves applying electromagnetic radiation to chemical reactions. This 
heating involves conversion of electromagnetic energy to thermal energy, which is dependent 
on the dielectric constant of the material irradiated. Solvents with a high dielectric constant 
such as water (H2O) and dimethylformamide (DMF) are heated rapidly with microwave 
radiation. However, those with a low dielectric constant, such as hexane (C6H14) and benzene 
(C6H6), do not couple and therefore do not heat rapidly using microwave radiation. The 
heating effect utilized in microwave assisted transformations is mainly due to change in 
dipole moment caused by the interaction of the molecule with the radiation. Microwave-
assisted synthesis has many advantages reported by Kappe and other researchers.
1-3
 These 
includes the following: 
i. Reduced solvent usage 
ii. Accelerated reaction rate 
iii. Reduced reaction time 
iv. Higher product yield 
v. Milder reaction conditions 
vi. Different reaction selectivities 
vii. Broad applicability – few limitations as to the type of synthesis chemistry 
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These advantages have attracted a lot of research using microwave reactors in synthesis. 
Organic synthetic chemists have long enjoyed the benefits that microwave heating affords.
4-7
 
In contrast, fewer reports on the use of microwave reactors in preparation of organometallic 
compounds are available.
8-10
 Early work on preparation of organometallic compounds was 
carried out in 1989, a few years after pioneering work in microwave-assisted organic 
synthesis. This work involved synthesis of rhodium(I) and iridium(I) dimers of the type  
[M2Cl2(di-olefin)2]  from metal halides, MCl3, in alcoholic solvent.
11
 A year later various 
complexes were prepared using a similar methodology. The reaction rates were demonstrated 
to have been dramatically increased and product yield improved compared to conventional 
method of synthesis. Lasri also demonstrated reactions that were accelerated using 
microwave reactors in the synthesis of palladium tetrazolato complexes.
12
  
Not only can microwave heating reduce reaction time of known reactions but it can also 
result in new chemistry. Pyper and colleagues reported the one-step preparation of 
compounds of the type [Os2(-O2CR)2(CO)6].
3
 They obtained higher yields and their reaction 
did not require an inert environment compared to conventional technique. The reaction rate 
can also be manipulated by choice of solvent. Subsequent studies have shown that microwave 
heating is effective in synthesis of a variety of metal-containing compounds using simpler 
procedures and/or fewer steps than previously reported. The microwave heating technique 
has proved most fruitful. 
Monitoring of reactions in a microwave reactor has been a limitation, however the group of 
Leadbeater was able to overcome this problem using in situ Raman spectroscopy to monitor 
substitution reaction of Mo(CO)6.
2
 
To the best of our knowledge no previous work has been reported on microwave-promoted 
reactions of [OsX6]
2-
, including its conversion to [OsX2(PP)2]. 
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3.1.2 OsX2(PP)2 complexes 
 
Transition metal complexes bearing chelating diphosphine ligands have enjoyed widespread 
interest for several decades. This is owed to their potential use as catalysts, molecular 
electronic devices and use in organic synthesis.
13-16
 Steric and electronic effects as well as the 
chelate ring size have been found to influence the reaction rate, stability and selectivity of 
these complexes.
17
  
The chemistry of transition metal-halide complexes containing diphosphine ligands of the 
type [MX2(PP)2]  (M = Ru, Os; PP = diphosphine ligand) is well established. Considerable 
research demonstrates the use of these complexes as precursors for preparation of complexes 
which have found use in various applications.
18-24
 These complexes have properties that make 
the compounds useful molecular electronic components. Some of these properties are 
achieved by replacement of the halide ligand with aliphatic or benzylic amines or an electron 
rich ligand which led to preparation of complexes with interesting electrochemical 
behaviour.
24
 
3.1.3 Preparatory methods  
  
Complexes of the type [MX2(PP)2] are commonly prepared by applying methods first 
reported by Chatt and Hayter.
25
 Their work involved the reaction of metal halides, such as 
RuCl3 and (NH4)2OsCl6, as precursors with excess diphosphine ligand in alcohol medium 
(Scheme 3.1). This method afforded trans-[MCl2(PP)2] {PP = C2H4(PR3)2 (R = Me, Et, 
Ph), CH2(PPh2)2 and  o-C6H4(PEt2)2 (Scheme 3.1 Eq 1) in 30 – 80% yield. The cis isomer is 
obtained via a different method which involves the substitution of a monophosphine ligand 
with a diphosphine ligand in the absence of a solvent at high temperatures. This method also 
demonstrated that an increase in the alkyl group spacer in the diphosphine ligands affects the 
stereochemistry of the product. Reaction with dppm ligand gave the cis-isomer while dppe 
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gave  trans isomer. The cis isomers can also be prepared using a dinuclear complex, 
[M2Cl3(PR3)6], as a precursor by reacting with diphosphine ligand in absence of a solvent at 
high temperatures (Scheme 3.1 Eq 2). Chatt and Hayter also demonstrated preparation of cis 
complex by isomerisation of trans-complex in the presence of excess of aluminium trialkyls 
AlR3 (R = Me, Et or Pr
n
) (Scheme 3.1, Eq 3).  Metathetical replacement using the appropriate 
salt can also produce these complexes (Scheme 3.1, eq. 4).  
 
Scheme 3.1: Synthesis of [MX2(PP)2] (where M = Ru, Os; X = Cl, Br; PP = diphosphine 
ligand) reported by Chatt and Hayter.
25
 
 
Recently, Al-Noaimi modified one of Chatt procedures. He prepared the trans-[RuX2(PP)2] 
complexes from [RuCl2(PPh3)3] by stirring at room temperature for less than an hour and 
obtained high yields (Scheme 3.2).
26
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Scheme 3.2: Synthesis of [OsCl2(PP)2]  (PP = diphosphine ligand) reported by Al-
Noaimi.
26
 
 
An alternative approach was developed by McDonagh and coworkers (Scheme 3.3). They 
show selective preparation of either cis or trans-isomers of the diphosphine complex from 
DMSO substituted complexes cis/trans-[OsCl2(DMSO)4].
27
 
 
   
 
Scheme 3.3:  Synthesis of cis/trans-[OsX2(PP)2] reported by the group of McDonagh.
27
 
3.1.4 Focus of this study 
 
In this section we report a synthetic strategy for the convenient preparation of Os(II) halido 
complexes containing chelating P donor ligands (PP = dppm, dppe, dppp) using microwave 
heating techniques (Scheme 3.4). Direct reduction of the osmium salt, Y2[OsX6]
  
(Y = NH4, 
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K; X = Cl, Br, I) in alcohol solvent is achieved. Chart 3.1 is a representative of complexes 
synthesised in this chapter. 
    
Chart 3.1: List of Os(II) halide diphosphine complexes prepared in this study. 
3.2 Synthesis 
  
Direct reduction of [OsX6]
2-
 is accomplished in the presence of the diphosphine ligands via a 
dissociative substitution pathway (Scheme 3.4). In this mechanism, the metal-halide bond is 
fully broken before the metal-phosphine bond is formed.  
 
Scheme 3.4: Dissociative ligand substitution pathway. 
Excess diphosphine ligand allows subsequent substitution of halide ligand with formation of 
chelate ring. 
Reaction of [OsX6]
2-
 with 4 equivalents of 1.1-bis(diphenylphosphino)methane, dppm, in 2-
methoxyethanol under microwave (MW) irradiation (30 min, 80 °C, 200 W) produced only 
the cis isomer identified by 
31
P NMR spectroscopy. This reaction selectively gave cis isomers 
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of [OsX2(PP)2]. However, using the same reaction conditions where PP = dppe, dppp, 
produced trans isomers (Scheme 3.5). Increasing the number of methylene groups in the 
spacer between the two phosphorus atoms exerts significant steric influence. Also increasing 
the bite angle (Figure 3.1) of diphosphine ligands has an effect on the stereochemistry of the 
product. Diphosphine ligands with small bite angles occupy equatorial and axial positions. As 
the bite angle increases the diphosphine ligand preferentially occupies a pair of equatorial 
positions to avoid steric hindrance. The effect of the bite angle on the regioselectivity is 
explained by the steric crowding at the metal centre as a consequence of interaction of phenyl 
groups. Thus, dppe and dppp occupies the equatorial positions.
28
   
     
Figure 3.1: Structure illustrating bite angle. 
The desired Os(II) halide phosphine complexes are formed in moderate to high yield, 25-
92%. The complexes are characterized by 
1
H and 
31
P NMR spectrometry as well as  FT-IR 
and Raman vibrational spectroscopy. 
 
Scheme 3.5: Microwave-promoted synthesis of complex 5a-7c. 
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3.3 Results and discussion 
 
The complexes [OsX2(PP)2] 5a-7c were characterized using NMR spectroscopy, as well as 
solid state FT-IR and Raman spectroscopy. 
3.3.1. 
1
H NMR spectroscopy 
 
The NMR spectra of complexes 5a-7c were recorded in CDCl3 and chemical shifts are given 
in Table 3.1. Slow decomposition of products in solution with time was observed in the 
spectra with broadening of the signals in most complexes. 
The 
1
H NMR spectra of the prepared complexes featured characteristic resonances arising 
from diphosphine ligands (dppm, dppe, dppp). Integration of the 
1
H resonance confirms the 
PP ratio is in agreement with the structural composition cis-[OsX2(PP)2], 5a-c, and trans-
[OsX2(PP)2], 6a-7c. The complexes cis-[OsX2(dppm)2], X = Cl, Br, I exhibited similar 
1
H 
NMR spectra  showing two types of resonances assigned to methylene and aromatic protons. 
Change in halide ligands influences the resonance as shown by difference in methyl and 
aromatic chemical shifts for complex 5a (4.40, 5.90, 6.47 – 8.12 ppm), 5b (4.79, 5.93, 6.63 – 
8.22 ppm) and 5c (4.92, 6.10, 6.63 – 8.29 ppm). Deshielding is affected by the -bonding 
capabilities of the halides. 
 
 
 
 
 
 
67 
 
Table 3.1: NMR spectroscopic data for cis-[OsX2(PP)2] complexes. Recorded in CDCl3. 
Complex P{1H}) ppm (1H NMR) ppm 
free ligand (dppm) -22.2 2.84 (s, 1H, CH2), 7.32 (s, 
12H, Ar), 7.46 (s, 8H, Ar) 
5a  4.40(s, 2H, CH2), 5.90 (s, 
2H, CH2), 6.47 – 8.12  (m, 
40H, Ar)  
5b -72.8 (t, J(PP) = 46.0 Hz),        
-57.9 (t, J(PP) = 46.0 Hz) 
4.87 - 4.69 (m, 2H, CH2), 
6.02 - 5.85 (m, 2H, CH2), 
6.63 – 8.22 (m, 40H, Ar) 
5c -83.5 (t, J(PP) = 44.8 Hz), -
64.4 (t, J(PP) = 44.8 Hz) 
4.99 - 4.84 (m, 2H, CH2), 
6.19 - 6.02 (m, 2H, CH2), 
6.63 – 8.23 (m, 40H, Ar) 
  
The chemical shifts of the methylene as well as the aromatic protons of the coordinated 
diphosphine ligands occur downfield compared to the free ligands. It is clear that 
complexation to the metal has a marked influence on the chemical shift of the protons. The 
downfield shift is caused by withdrawal of the electron density from the diphosphine ligand 
to the metal centre, deshielding the nucleus and shifting downfield.  
The 
1
H NMR spectrum of complex 5b exhibits resonances assigned to methylene and 
aromatic protons (Figure 3.2). The two CH2 groups resonate as two sets of broad multiplets at 
 5.93 and 4.79 ppm intergrated to 1:1 ratio. This is an indication that the two protons on CH2 
are diastereotopic (AB spin pattern).
29
 This has been reported before for the cis-
[Ru(dppm)2C2O4], cis-[Ru(dppm)2(N3)2] and cis-[Ru(dppm)2ClN3] complexes.
24
 The 
multiplet nature is due to the 
1
H-
1
H and 
1
H-
31
P coupling. 
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Figure 3.2: 
1
H NMR spectrum of cis-[OsBr2(dppm)2], 5b. 
 
The aromatic region in the spectrum consists of several coupled multiplets due to the 
aromatic protons of the phenyl rings of the diphosphines. The distinct proton signals for the 
phenyl rings indicate the different environment, phenyl protons in cis position with the halide 
exhibits resonances further downfield and those that are in trans arrangement with the halide 
are upfield. 
The NMR spectra of the complexes 6a-c exhibit resonances assigned to the aromatic and 
methylene protons (Table 3.2). The 
1
H NMR spectrum of complex 6b is shown in Figure 3.3. 
The 4 methylene protons resonate as two broad singlets at   2.60 and 2.13 ppm intergrated to 
a 1:1 ratio. This is an indication that the two protons on CH2 are diastereotopic (AB spin 
pattern). A downfield shift is also observed with change in X for complex trans-
[OsX2(dppe)2] with the iodido complex showing chemical shifts at higher resonance and the 
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chlorido complex at lower resonance (Table 3.2). A consequence of -bonding capabilities of 
halide ligands. 
Table 3.2: NMR spectroscopic data for trans-[OsX2(PP)2] complexes. Recorded in CDCl3. 
Complex P{1H})  (1H NMR) 
Free ligand (dppe) -12.6 2.13 (s, 2H, CH2), 7.34 (d, J = 12.0 Hz, 
20H) 
6a  2.29 (s, 4H, CH2), 6.92 - 7.45 (m, 20H, 
Ar)  
6b 29.6 (s) 2.13 (s, 2H, CH2), 2.67 (s, 2H, CH2), 6.96 
- 7.27 (m, 20H, Ar)  
6c 26.5 (s) 2.12 (s, 2H,CH2), 2.67 (s, 2H, CH2), 6.70 
– 7.91 (m, 20H, Ar) 
Free ligand (dppp) -17.5 1.66 (m, 2H, CH2), 2.24 (m, 4H, CH2), 
7.30 (m, 12H, Ar), 7.37 (d, J = 38.6 Hz, 
8H, Ar) 
7a  2.38 (m, 3H, CH2), 3.07 (m, 3H, CH2), 
6.85 – 7.35 (m, 20H, Ar 
7b  -25,2 (s) 1.58 (d, J = 12.2 Hz, 4H), 2.39 (m, 2H, 
CH2), 3.07 (m, 2H, CH2), 7.11 (m, 40H, 
H-aromatic) 
7c 31.9 (s) 2.48 (m, CH2), 3.10 (m, CH2), 6.86 – 7.68 
(m, 20H, Ar) 
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Figure 3.3: 
1
H NMR spectrum of trans-[OsBr2(dppe)2], 6b. 
The 
1
H NMR spectrum of 7b exhibits proton signals of phenyl groups as multiplets in the 
range  6.85 – 7.35 ppm, and signals of methylene protons at  3.07, 2.38 and 1.58 ppm, their 
peak intergration ratio is about 10:1:1:1 (Figure 3.4). The methylene protons give rise to three 
resonances because the protons are diastereotopic. The strong P-trans-P coupling gives rise to 
the multiplet pattern seen in the alkyl region.
23
 A downfield shift is observed with change in 
X with the iodido complex 3c showing resonances at higher frequencies compared to the 
bromido and chlorido complex. 
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Figure 3.4: 
1
H NMR spectrum of trans-[OsBr2(dppp)2], 7b.    
   
3.3.2  
31
P{H} NMR spectroscopy 
 
The 
31
P NMR data for complexes 6a-7c are given in Table 3.2. The cis and trans isomers are 
easily distinguished by their 
31
P NMR spectra. The 
31
P NMR spectra of cis complexes show a 
pair of triplets which suggests that two pairs of P atoms that are magnetically inequivalent.
26
 
The 
31
P{H} NMR spectra of the trans isomer exhibits a singlet which suggets the presence of 
four equivalent nuclei. 
The 
31
P{H} NMR spectrum in CDCl3 solution show a pair of triplets at  -72.8 and -57.9 (t, 
J(PP) = 46.0 Hz) ppm for 5b (Figure 3.5) ,  -83.5 and -64.4 (t, J(PP) = 44.8 Hz) ppm for 5c. 
The shielded signal is assigned to the pair of phosphorus atoms cis to the halides and the 
deshielded signal is due to the phosphorus atoms trans to the halides, which is consistent with 
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the proposed structure in which halides are mutually cis.
30,31
 Unfortunately, attempts to 
observe 
31
P{H} NMR spectrum for complex 1a were unsuccessful. 
 
Figure 3.5: 
31
P{H} NMR spectrum of cis-[OsBr2(dppm)2], 5b. 
A decrease in chemical shift and J coupling constant is observed as X is varied from Br to I 
in the cis-[OsX2(PP)2] complex. The decrease in coupling constant is in agreement with the 
order of trans influence of I  Br  Cl.32  
The 
31
P NMR spectra exhibit a sharp singlet at  23.0 ppm for 6b (Figure 3.6), at  26.4 ppm 
for 6c, at  -25.2 for 7b and at  32.4 ppm for 7c. The singlet suggests that the P atoms in 
these complexes are chemically and magnetically equivalent, which suggests that the 
phosphine ligands occupy the equatorial positions with halide ligands trans to each other. 
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The difference in 
31
P NMR chemical shift can be explained by the size of the cone angle. As 
this angle increases, the phosphorus chemical shift moves upfield. Analyses of the 
31
P NMR 
data obtained reveal that the ring size of the chelating phosphine ligand also contributes to the 
chemical shift. As explained by Slack and Baird, the 5-membered ring has positive 
(deshielding) ring contributions while the 4 and 6-membered rings have negative (shielding) 
contributions to the chemical shift as observed in 
31
P NMR spectra of 6b-7c.
26,33,34
 It has been 
suggested that the shift is a consequence of a large ring strain introduced by the 5-membered 
chelate ring. An extremely large downfield shift of the P nuclei occurs upon complexation of 
the dppe ligand. This is also observed in complexes containing phosphorus in 5-membered 
ring.
26,30
 
 
Figure 3.6: 
31
P NMR spectrum of trans-[OsBr2(dppe)2], 6b. 
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 3.3.3 FT-IR  spectroscopy 
 
The IR data of complexes 5a-7c are given in Table 3.3. These complexes show four sets of 
characteristic absorptions in the ranges 3000 - 3100, 2984 – 2912, 1588 - 1572 and 1090-
1087 cm
-1
, which can be assigned to aromatic C-H stretches, alkane C-H bending,  and P-Ar 
stretches respectively (Figure 3.7). 
 
Table 3.3: Selected IR spectroscopic data. 
Complex                                         IR stretches (cm
-1
)
a
 
 Aromatic CH Alkane CH Aromatic C=C P-Ar 
5a 3055      2913      1572 1090 
5b 3070       2984      1572 1093 
5c 3045       2913      1584 1090 
6a 3052       2917       1585 1090 
6b 3071      2922      1585 1088 
6c 3050     2950      1583 1087 
7a 3046      2925      1588 1090 
7b 3047     2912     1585 1091 
7c 3071     2940     1585 1089 
 
a
Recorded in solid state          
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Figure 3.7: Solid FT-IR spectrum of complex cis-[OsI2(dppm)2]. 
 
3.3.4  Thermogravimetric analysis 
 
Thermal decomposition of the complexes was studied and found to be a two-stage process 
that can be directly related to the ligands loss. The studies were carried out in the 100 – 1300 
°C temperature range under nitrogen gas at a heating rate of 10 °C/min. The first stage is 
associated with loss of halides and second stage associated with loss of diphosphine ligand 
(Figure 3.8 – 3.10). Onset of decomposition is at 370, 374 and 343 °C for complex 5a, 5b and 
5c, respectively (Figure 3.8).  The trans complexes 6a, 6b and 6c are stable to temperatures 
just above 300 °C (Figure 3.9). Complexes 7a, 7b and 7c start to decompose in the range 195 
– 251 °C (Figure 3.10).  
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Figure 3.8: Thermogram showing decomposition of complexes 5a-c. 
 
Figure 3.9: Thermogram showing decomposition of complexes 6a-c.  
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Figure 3.10: Thermogram showing decomposition of complexes 7a-c.  
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3.4 Conclusions 
Complexes cis-[OsX2(dppm)2] (where X = Cl, Br, I) and trans-[OsX2(PP)2] (X = Cl, Br.I; 
PP = dppe, dppp) are conveniently prepared directly from [OsX6]
2-
 in high yield with the 
use of microwave heating. The use of a microwave reactor greatly reduces the reaction time 
compared to conventional methods with the complexes prepared in minutes instead of hours. 
The reactions are less complex and require fewer reagents. The solvent usage is significantly 
reduced. We have also demonstrated that it is not necessary to carry out this synthesis under 
inert conditions. With isolated yields up to 92%, the yields are better than those obtained by 
conventional methods. Product purity was established by 
31
P NMR spectroscopy. 
Increasing the alkyl spacer group between to the P atoms of diphosphine ligand has a 
pronounced effect on the outcome of the reaction. Reaction of [OsX6]
2-
 with dppm selectively 
yields cis-[OsX2(dppm)2] (X = Cl, Br, I). Under the same reaction condition dppe and dppp 
each reacts with [OsX6]
2-
 to give trans geometric complexes. It is hypothesised that the cis-
isomer is formed and subsequently isomerises to the trans-form because of the sterically 
demanding phenyl rings. 
The aromatic signals in the 
1
H NMR spectra of complexes consists of several coupled 
multiplets due to aromatic protons of the phenyl rings of the diphosphine ligands and 
resonance is observed in the alkyl region for methylene protons. The 
31
P{H} NMR spectra of 
trans-[OsX2(PP)2] (where PP = dppe, dppp; X = Cl, Br, I) shows a singlet suggesting that 
the four phosphorus atoms of the chelating ligands are magnetically equivalent. From 
31
P 
NMR data it can be seen that the preferred ring size for formation of cis-[OsX2(PP)2] are 4-
membered chelating rings and trans-[OsX2(PP)2] is preferred for 5- and 6-membered 
chelating rings. There are a number of published methods for preparation of these complexes 
of the type [OsX2(PP)2] but microwave-assisted synthesis was found simple, convenient  
79 
 
and a selective synthesis method which improved reaction  rates and improved product 
yields. 
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Chapter 4 
Microwave-promoted synthesis of phosphine-
substituted osmium carbonyl cluster complexes. 
4.1 Introduction 
4.1.1 Triosmium carbonyl cluster complexes 
 
Clusters are defined as compounds containing two or more metal-metal bonds.
1
 Transition 
metal clusters have several important properties relative to their mononuclear counterparts. 
The polynuclear framework is unique because ligands are able to coordinate to more than one 
metal centre.  
The organometallic cluster compound triosmium dodecacarbonyl, [Os3(CO)12], can undergo a 
wide range of chemical reactions to produce a variety of products, often with no change in 
nuclearity. Many different ligands have been used in these reactions for development of 
triosmium clusters that can be used in various applications. The wealth of chemistry of 
triosmium clusters has led to the rapid growth of research and preparation of cluster 
compounds that has found application in catalytic systems
2-5
 and more recently in  
chemotherapy.
6,7
 
The chemistry of phosphine-substituted derivatives of [Os3(CO)12] has been extensively 
studied.
8-15
 Phosphines, PR3, find widespread use as ligands in coordination chemistry 
because they constitute one of the few ligands in which the steric and electronic properties of 
the ligand can be easily tunable by varying the R group. Diphosphine ligands give extra 
stability in complexes as a result of their ability to chelate metal centres.
16
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4.1.2 Preparatory methods 
 
4.1.2.1 [Os3(CO)12]   
The cluster [Os3(CO)12] was first prepared by Hieber and Stallman in 1943.
17
 The initial 
method of preparation involves direct reaction of osmium tetroxide, OsO4, with CO gas. They 
obtained two products which they formulated as [Os(CO)5] and [Os2(CO)9].
17
 However, the 
latter was later shown to be [Os3(CO)12] via X-ray crystallographic studies and trimeric 
formulation.
18,19
 The little yield of [Os3(CO)12] obtained using method by Hieber hindered its 
use. Several routes that involve preparation of the cluster have since been reported. Bradford 
and co-workers reported a method with improved yields of approximately 70%. The method 
involves reaction of OsO4 with CO gas in xylene.
20
 A popular method for preparation of 
[Os3(CO)12] involves carbonylation of osmium tetroxide in a methanol solution at moderate 
pressure (75 atm) and temperature (125 °C) for 12 h.
21
  
Osmium tetroxide, OsO4, is a toxic material and makes the preparation of osmium carbonyls 
difficult. Roveda and colleagues demonstrated the synthesis of [Os3(CO)12] in 65% yield 
under mild conditions by silica-mediated reductive carbonylation of the non-toxic 
[Os(CO)3Cl2]2 or [Os(CO)3Cl2(HOSi)]. [Os(CO)3Cl2]2 in presence of the base Na2CO3 at 1 
atm of carbon monoxide at 160 - 165 °C.
22
 Bruce and co-workers reported the preparation of 
[Os3(CO)12] from a stable osmium-halide precursor such as ammonium hexabromoosmate in 
the presence of zinc using methanol as a solvent. In this method [Os3(CO)12] is prepared in 
carbon monoxide gas under pressure between 4 to 25 atm. 
4.1.2.2 [Os3(CO)12-n(PR3)n] 
The common method of preparing phosphine-substituted triosmium clusters involve the use 
of the labile cluster complexes [Os3(CO)11CNMe] and [Os3(CO)10(CNMe)2] as precursors 
(Scheme 4.1, Eq 4.1).
8,10-12,14,23-27 
Direct reaction of the [Os3(CO)12] cluster complex with 
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phosphines has also been reported in literature (Scheme 4.1, Eq 4.2). This method yields a 
mixture of phosphine-substituted products. Thermal reaction of [Os3(CO)12] with phosphine 
ligands was found to give a mixture of products.
9,28-30
  Leadbeater
29
  and Poe
30
 have 
demonstrated the photochemical synthesis of [Os3(CO)12-n(PR3)n] (where n = 1-3) from 
[Os3(CO)12] solution in the presence of phosphine ligands (Scheme 4.1, Eq 4.3).  
 
Scheme 4.1: Preparatory methods of [Os3(CO)12-n(PR3)n] (n = 1-3). 
 
4.1.2.3 [Os3(CO)11{-(PP)}], [Os3(CO)10{-(PP)}] and [Os3(CO)10{
2
-(PP)}]  
The reactivity of cluster compound with bidentate phosphine ligands, Ph2P(CH2)nPPh2, have 
also been investigated. The ability of the ligands to chelate thus increasing the stability of the 
metal framework is an interesting property. These complexes are commonly prepared from 
labile cluster complexes [Os3(CO)11CNMe] and [Os3(CO)10(CNMe)2]. Reactivity of the 
activated cluster with diphosphine ligands yields [Os3(CO)11(PP)] and [Os3(CO)10(PP)], 
respectively.
25
 In the latter cluster, the diphosphine ligand can chelate to a single metal atom 
or bridge two adjacent metal atoms. Example of chelating and bridging [Os3(CO)10(PP)] are 
shown in Figure 4.1 
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Figure 4.1: Examples of bridging and chelating isomers of [Os3(CO)10(PP)]. 
 The use of microwave irradiation in synthesis is rapidly increasing and has found widespread 
use.
31-35
 A number of recent studies have investigated the microwave-promoted 
transformation of [Os3(CO)12] into other trinuclear clusters.
6,13,36
  Microwave heating usually 
produce higher product yield, increase reaction rates, reduced reaction time and milder 
reaction conditions. This method yields substituted triosmium clusters directly without the 
use of the labile cluster [Os3(CO)12-n(CNMe)n] (where n = 1-2).  
 
4.1.3 Focus of this study 
 
We have studied the reactivity of [Os3(CO)12] with PPh3 and dppm in a microwave reactor. 
Also the effect of different solvents in the reaction of PPh3 with [Os3(CO)12] was evaluated. 
Our studies have shown that by microwave irradiation of [Os3(CO)12]  in varying solutions in 
the presence PPh3 produce different substituted products. Similar work has been done with 
UV irradiation of [Os3(CO)12] in the presence of PPh3, which led to formation 
photosubstituted product [Os3(CO)12-n(PPh3)n] (n = 1-3). The use of hexane as a photolysis 
media led to photofragmentation of the cluster and yield mononuclear Os(CO)3(PPh3)2.
29
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4.2 Synthesis 
 
Bruce’s approach with slight modification was used in the preparation of [Os3(CO)12]. Higher 
pressures and temperatures are used in this study. Reaction of the osmium halide precursor, 
ammonium hexachloroosmate(IV), (NH4)2[OsCl6] in methanol at 140 °C under pressurized 
carbon monoxide in the presence of zinc leads to formation of [Os3(CO)12] in 64% yield 
(Scheme 4.2).  
 
Scheme 4.2: Preparation of [Os3(CO)12]. 
Microwave irradiation of [Os3(CO)12] in acetonitrile solution in the presence of 
triphenylphosphine resulted in substitution of CO ligands to give a mixture of two products, 
the trisubstituted [Os3(CO)9(PR3)3] complex (10) and disubstituted [Os3(CO)11(PR3)2] 
complex (11) (Scheme 4.3). This method represent a fast and efficient route of synthesizing 
phosphine-substituted clusters directly from [Os3(CO)12] without initial preparation of the 
activated cluster.
11
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Scheme 4.3: Preparation of triphenylphosphine-substituted triosmium cluster complexes via 
microwave irradiation. 
Microwave heating of [Os3(CO)12] in the presence of PPh3 in other solvents (DCM, DCE, 
CHCl3) gives a mixture of substituted products. Unfortunately, the products were not 
separated chromatographically and could be identified using 
31
P NMR. The mixture contains 
[Os3(CO)11(PPh3)], [Os3(CO)10(PPh3)2] and triphenylphosphine oxide. 
Reaction of [Os3(CO)12] and dppm via microwave heating gives a single product identified as 
[Os3(CO)11(
1
-dppm)] (Scheme 4.4). However, this reaction gives [Os3(CO)10(-dppm)] 
when carried out by conventional methods.  
 
Scheme 4.4: Microwave preparation of [Os3(CO)11(
1
-dppm)]. 
Based on the intensities of the signals in 
31
P NMR spectra the major product in the mixture is 
complex 11 in all the solvents used. Dichloroethane as a solvent yields a single product based 
on 
31
P NMR spectrum. No further characterization was done. 
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4.3 Results and discussions 
 
The Os(0) carbonyl clusters complexes were characterized in solution using NMR 
spectroscopy and IR as well as solid state Raman spectroscopy. 
4.3.1 IR and Raman spectroscopy 
 
The IR data of complex 9-12 are given in Table 4.1. The data indicate that increasing 
substitution from the parent carbonyl cluster 9 leads to progressive lowering of the remaining 
CO stretching frequencies.  
The FT-IR spectrum of cluster complex 9 in CH2Cl2 shows four principal carbonyl stretching 
vibration bands in the region 1900 - 2100 cm
-1 
(Figure 4.2), as expected for a D3h symmetry. 
The spectrum is similar to that reported in literature.
29,37
 The carbonyl absorptions are 
grouped into two groups, the axial and equatorial, which have a different bond order due to -
bonding effects. Axial CO ligands compete for the same -electrons and have slightly higher 
bond order than each of the carbonyls in equatorial position. It is therefore expected for the 
equatorial modes to be centered at a lower energy than the axial modes.  
The Raman spectrum of complex 9 shows presence of bands in the region 1900 – 2100 cm-1 
(Figure 4.2). These bands can be satisfactorily attributed to CO stretching vibrations.38 The 
centrosymmetric complexes show an infrared-Raman exclusion although near-coincidences 
occur. There is no significant distinction between the IR and Raman spectra. A similar 
general peak pattern is observed. However, the intensities of the bands are different. The 
raman spectrum shows medium to low intensities whilst the corresponding IR spectrum 
shows very intense bands as expected. This can be explained by the different principles. 
Raman bands depend solely on the relative orientations of the CO groups and not the bonding 
within the molecule. Vibrations involving polar bonds are weak Raman scatterers. The 
intensity of the bands in IR is dependent on the polarity of the bond.  
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Table 4.1: IR data in the carbonyl region of complex 9 - 12. 
Complexes IR (CO, CH2Cl2) cm
-1
 
9 2060(s), 2037(vs), 2015(s), 1995(s) 
10 2049(w), 2023(m), 1996(m), 1964(vs), 1940(w) 
11 2984(w), 2055(m), 2029(m), 1996(s), 1967(mw) 
12 2109(w), 2061(m), 2047(mw), 2020(mw), 1999(s), 1965(m) 
 
 
       
Figure 4.2: FT-IR and Raman spectra of cluster complex 9.
19-20
 
 
The IR data of complex 10-12 is similar to data previously reported,
29,39
 with cluster complex 
[Os3(CO)9(PPh3)3] (10) and [Os3(CO)10(PPh3)2] (11)  exhibiting a carbonyl stretching patterns 
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that are similar to a typical trisubstituted and disubstituted-phosphine cluster [Os3(CO)12-
n(PR3)n], respectively. The carbonyl stretching pattern of complex 12 corresponds to 
triosmium clusters with diphosphine ligand coordinated in a monodentate mode. IR spectra of 
the products obtained from reaction of [Os3(CO)12] with PPh3 shows a pattern that is typical 
of a monosubstituted phosphine cluster complex. Raman spectra of complex 11 and 10 are 
given in Figure 4.4 and 4.3, respectively. These spectra provide further evidence for CO 
substitution.  
 
        
Figure 4.3: Raman spectrum of complex 10. 
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Figure 4.4: Raman spectrum of complex 11. 
 
4.3.2 NMR spectroscopy 
 
1
H and 
31
P NMR data for complexes 10 – 12 are given in Table 4.2. The chemical shifts of 
aromatic protons of the triphenylphosphine in 
1
H NMR spectra of complexes 10 and 11 is 
observed. A multiplet centred at  7.47 ppm is observed for complexes 10 and a multiplet 
centred at 7.45 ppm. The methylene protons of the 1-dppm ligand give rise to a triplet at  
4.77 ppm in the 
1
H NMR spectrum in addition to the aromatic protons (Figure 4.5). 
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Figure 4.5: 
1
H NMR spectrum of [Os3(CO)11(
1
-dppm)], 12. 
Table 4.2: 
1
H and 
31
P NMR for cluster complexes prepared.
a
 
Complexes  (1H NMR) ppm  (31P{H} NMR) ppm 
10 7.45 (m, 45H, H-aromatic) -2.29 
11 7.44 (m, 30H, H-aromatic) -1.76 
12 7.16 (m, 20H, H-aromatic), 4.77 (t, 
J(PH) = 7.8 Hz, 2H, CH2) 
-20.0 (d, J = 49.1Hz), -23.4 (d, J =  
49.1 Hz) 
a
 In chloroform solution 
Both complexes 10 and 11 exhibit a singlet in the 
31
P{H} NMR spectrum. A singlet at  = -
2.29 ppm for complex 10 and a singlet at  = -1.76 ppm for complex 11 are observed. This 
indicates that the phosphorus atoms occupy a similar environment. The phosphine ligands 
have been found to occupied the equatorial positions with respect to the triosmium plane. 
Two doublets at = -20.0 and -23.4 ppm are observed in the 31P{H} NMR spectrum of 
complex 12 (Figure 4.6). This data suggests that the phosphorus atoms are magnetically non-
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equivalent. The doublet in low-field is assigned to the coordinated phosphorus, whereas the 
uncoordinated phosphorus atom gives a signal in high field region. 
  
Figure 4.6: 
31
P NMR of complex 12. 
This data suggest that the diphosphine ligand has coordinated in a monodentate mode. The 
dppm ligand has the ability to either bridge two trinuclear metal complexes or chelate 
forming a 1,1-isomer. In this case either of the coordination mode is less likely the bulky 
phenyl rings limit the ability of dppm to bridge two Os3(CO)11 fragments. Also chelation is 
not favourable presumable because of the strain in a 4-membered ring, in addition chelation 
will cause distortion from an octahedral geometry which is not favourable.
39
   
The 
31
P NMR spectra of product where DCE, DCM and CHCl3 are used as solvents in the 
microwave irradiation of [Os3(CO)12] and PPh3 exhibit 3 signals indicating the presence of 3 
isomers. The resonance at d -1.74 ppm is identified as [Os3(CO)10(PPh3)2].  Resonance at  -
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10.3 ppm is not identified but it is hypothesized to be the monosubstituted phosphine cluster 
based on the combination of 
31
P NMR and the IR spectroscopic data. As discussed above a 
pattern in the CO region of a typical monosubstituted triosmium cluster. Unfortunately, the 
product was not chromatographically separated and thus no further characterization was 
done. A small third signal at  28.5 ppm is likely the triphenylphosphine oxide. 
13
C NMR could not be obtained. This is caused by carbonyl undergoing  axial-equatorial 
fluxional mechanism. At temperatures above -50 °C selective carbonyl exchange occurs in 
these complexes which cause the resonance to broaden and collapse to the baseline at 
different rates.
10,15,40,41
  
4.3.3 Thermogravimetric analysis (TGA) 
 
Thermal decomposition studies of complexes 9-11 were carried out. The data show that the 
phosphine-substituted cluster complexes, 10 and 11, are thermally more stable compared to 
the parent triosmium carbonyl cluster, complex 9.  Complex 9 when heated was found to be a 
single stage process. The onset of decomposition occurs between 180 – 246 °C. At this 
temperature to about 246 °C a total decomposition of the cluster is observed. 
Onset of decomposition for complex 10 is ca. 213 °C. The initial stage of decomposition is 
accompanied by 10.5% mass loss associated with the loss of five CO ligands. The second 
stage (265 – 455 °C) is associated with loss of the remaining CO ligands and two PPh3. The 
third PPh3 is lost at temperatures above 1000 °C.  
Complex 11 was found to undergo a multistage process of decomposition. The stages can be 
directly related to the loss of ligands. The first stage between 209 – 238 °C was accompanied 
by an 8.2% mass loss associated with the release of four carbonyl ligands. We hypothesize 
that these four are the axial carbonyls on the metal center where the phosphine is coordinated. 
The MCO axial bonds of the Os(CO)4 center are much stronger than the other axial bonds 
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and hence the CO ligands are lost in second stage of decomposition along with the equatorial 
CO ligands and one triphenylphosphine. The second stage (238 – 468 °C) and the third stage 
(468 – 968 °C) involved loss of remaining PPh3 ligand.  
  
Figure 4.7: Thermogram of cluster complexes 9, 10 and 11. 
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4.4 Conclusions 
 
Microwave-promoted conversion of [Os3(CO)12] allows for fast and efficient synthesis of 
substituted trinuclear cluster derivative. Microwave irradiation of a mixture of [Os3(CO)12] 
and PPh3 gave a mixture of phosphine substituted  cluster complexes. It is worth noting that 
these substituted clusters are obtained directly from the parent carbonyl [Os3(CO)12]. This 
eliminates the multi-step method described in literature for synthesis of similar cluster 
complexes which involves activation of the parent cluster Os3(CO)12 to labile cluster 
complexes, [Os3(CO)11(CNMe)] and [Os3(CO)10(CNMe)2], with subsequent reaction with 
relevant ligand. Microwave reaction of [Os3(CO)12] and dppm leads to formation of 
[Os3(CO)11(dppm)], complex 12, as the only isolable product. 
We have also studied the ligand substitution reaction of [Os3(CO)12] with triphenylphosphine 
in different solvent such as CH2Cl2, C2H4Cl2 and CHCl3. In this case the disubstituted 
phosphine complex [Os3(CO)10(PPh3)2] is a minor product in addition to the monosubstituted 
complex [Os3(CO)11(PPh3)] which appears as an intense peak in the 
31
P NMR spectrum. No 
trisubstituted [Os3(CO)11(PPh3)] complex was formed. 
Compared to conventional preparatory methods microwave heating produced desired 
complexes with fewer reaction steps and less solvent required. Complex 9 was found to be 
the least stable compared to the other complexes. On set of decomposition is at temperatures 
below 200 °C. Complex 10 and 11 showed thermal stability and started decomposition in 
temperatures just above 200 °C.  
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 Chapter 5 
In vitro antimicrobial and anticancer activities 
  
This chapter has two parts. The first part includes a brief background on the success of 
transition-metal antimicrobial agents. A brief section on the principle of laboratory methods 
used for screening antimicrobial agents is included.  Selected complexes prepared in this 
thesis were evaluated for antimicrobial activity and the results obtained are discussed. The 
second part gives a brief background on platinum containing complexes in the fight against 
cancer and the potential of non-platinum complexes as new anticancer agents is also 
discussed. In addition, some of the compounds prepared in this thesis were screened against 4 
human cancer cell lines. A conclusion on the overall results is given at the end of the chapter.  
5.1 In vitro antimicrobial screening 
5.1.1 Introduction 
 
Microbes are micro-organisms that can be divided into two groups depending on the type of 
cells they have. Those that have membrane-bound nuclei and other defined organelles are 
called eukaryotes which include fungi and protists. The other group of micro-organisms are 
called prokaryotes, these are identified by their lack of nuclei. They are unicellular organisms 
that lack organelles or other membrane-bound structures, an example is bacteria.
1
  
Bacterial and microbial infections are associated with the cause of high mortality and 
morbidity worldwide.
2,3
 Over centuries leading laboratories have made progress in the 
development of antimicrobials. It started with the accidental discovery of penicillin and later 
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its clinical use.
4,5
   Penicillin was found to have a wide spectrum of activity, including the 
ability to inhibit strains of Streptococcus and Staphylococcis. This was followed by 
development and subsequent clinical use of a number of related organic compounds.
6-8
  
Unfortunately, the success of these compounds has been hampered by resistance and decrease 
in efficacy. The micro-organisms developed resistance to multiple antimicrobial agents which 
consequently lead to treatment failures.
9
 Multidrug-resistant bacteria have become a global 
concern to public health. Hence, there is a great need for new compounds with antimicrobial 
activity with novel mechanisms of action.  
Metal-based antimicrobial agents tend to offer advantages over organic-based antimicrobial 
agents. The complexes offer a range of coordination geometries, different oxidation states 
and more stereochemical variability than is possible in organic molecules as well as the 
ability to influence the kinetic properties by rational design of the ligands which may be 
important for interaction with biomolecules. The metal complexes can also be charged and 
since many biological structures are also charged, possible electrostatic interaction could aid 
the binding with intracellular targets.  
A number of transition metal complexes have shown antimicrobial activities. These include 
Paul Erlich’s organoarsenic compound for treatment of syphilis.10 Copper-sulfonamide 
complexes have showed an increased activity compared to the free ligand.
11
 These copper 
complexes have been found to be active against Staphylococcus aureus and Escherichia coli. 
A range of metal complexes (Fe, Co, Ni, Cu, Cd, Zn and Mn) containing Schiff base ligands 
have demonstrated moderate antibacterial activity.
12
 Metal complexes offer novel mechanism 
of action not available to organic compounds. Phenanthroline and 2,2-bipyridine chelates of  
Ni, Fe, Zn and Rb have been reported to show activity against Gram-positive 
(Staphylococcus aereus, Streptococcus pneumonia and Clostridium perfringes) and Gram-
negative bacteria (Escherichia coli and Proteus vulgaris).
13
 It was hypothesized that 
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inhibition of growth of some microbes was a result of production of reactive oxygen species 
(ROS). Ruthenium(II) bis-(2,2’-bipyridine) complexes containing a N-phenyl-substituted 
diazafluorene ligand increased production of ROS in methillin-resistant Staphylococcus 
aureus.
14
 Labile ligands were reported to have an effect on the activity of complexes prepared 
by Ramos. The water-soluble ruthenium complexes containing PTA (1,3,5-triaza-7-
phosphaadamantane) and labile ligands (Cl, Br, I and SCN) were screened. Complexes 
containing Cl and SCN exhibited antifungal activity in contrast with Br and I containing 
complexes.
15,16
 
In this study, a series of complexes of osmium-phosphine complexes prepared were evaluated 
against well known multi-resistant bacteria and some strains of fungi. 
5.1.2 In vitro antimicrobial assays 
 
A variety of laboratory methods such as the disk-diffusion and broth and agar dilution 
methods can be used to evaluate the in vitro antimicrobial activity of compounds. To 
determine the minimum inhibitory concentration (MIC) values dilution methods are the most 
appropriate to employ. The objective of both agar and broth dilution methods is to determine 
the MIC of assayed antimicrobial agent that under tested conditions inhibits growth of the 
microbes being investigated either in agar (agar dilution) or broth medium (macrodilution or 
microdilution). These dilution methods can be used to quantitatively measure the in vitro 
antimicrobial activity against bacteria and fungi.  
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5.1.2.1 Agar dilution method 
This method involves incorporation of the antimicrobial agent into an agar, which is then 
placed in dilution plates and diluted to various concentrations with water. Followed by the 
inoculation of standard number of pathogens onto each plate. After incubation the lowest 
concentration of antimicrobial agent that completely inhibits growth is considered the MIC of 
that micro-organism. 
5.1.2.2 Broth dilution method 
Broth dilution method is often determined in a 96-well microtiter plate format. Two-fold 
dilutions of antimicrobial agent is prepared in liquid growth medium and added to the plate. 
Then each well is inoculated with the microbial inoculums prepared in the same medium. 
Growth is assessed after incubation for a defined period of time under suitable conditions 
depended upon the test micro-organism. The MIC is the lowest concentration of 
antimicrobial agent that completely stops the growth of micro-organisms in tubes or 
microdilution wells as detected visually. Tetrazolium salts such as 2-(4-iodophenyl)-3-(4-
nitrophenyl)-5-phenyl-2H-tetrazolium salt (INT) (Figure 5.1) is often used in the MIC 
endpoint determination for both antifungal and antibacterial microdilution assays. Broth 
micro or macro-dilution employs the same principle except the volume of the broth differs. 
Macro dilution uses a volume of about 1 mL in standard test tubes while microdilution uses 
about 0.05 – 0.1 mL total broth volume in a microtitre plate. However, unlike microdilution, 
the macrodilution method is tedious, and comparatively large amounts are required. 
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Figure 5.1: Structure of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium (INT) 
salt. 
    
5.1.3 Antimicrobial activity 
 
In this study 15 test compounds were evaluated in vitro for antimicrobial activity against 2 
Gram-negative strains (Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 
7700), 2 Gram-positive strains (Enterococcus faecalis ATCC 19433, Staphylococcus aureus 
ATCC 25925) and 2 fungal strains (Candida albicans ATCC 24433, Cryptococcus 
neoformans ATCC 14116).  
The antimicrobial activity of the compounds was evaluated using the microplate serial 
dilution assay.
17,18
 Bacterial cultures were maintained on Muller-Hilton (MH) agar and in 
MH broth at 37 °C for 14 h before being used in screening assays. The fungal strains were 
maintained on Sabouraud dextrose agar and Sabouraud dextrose broth prior to antifungal 
testing. Following incubation of the plates, the MIC values were determined in mg/mL. The 
results obtained were compared with those of the reference antimicrobial drugs Gentamicin 
and Amphotericin-B (Figure 5.2). 
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Figure 5.2: Chemical structure of reference antimicrobial agents 
 
Gentamicin is a type of aminoglycoside used to treat several bacterial infections. It has a 
broad spectrum of activity against bacterial infections mostly against Gram-negative bacteria 
such as Pseudomonas, Escherichia coli and Enterobacter aerogenes and Gram-positive 
Staphylococcus. It operates by inhibiting protein synthesis which leads to death of the 
pathogen. 
Amphotericin-B is a polyene used to treat a range of systematic fungal infections such as 
aspergillosis, blastomycosis, candida and cryptococcosis. At relevant clinical concentration 
Amphotericin-B is fungicidal. Amphotericin-B is associated with toxicities and is most 
commonly prescribed for patients who suffer from severe life-threatening invasive antifungal 
infection. This polyene antifungal agent exerts its activity by disruption of fungal cell wall 
synthesis. Due to its amphiphilic structure, these molecules bind to lipid bilayer and form a 
complex with the ergosterol pores causing disruption of the cell membrane. Disruption of the 
cell wall structure have an effect on the growth and morphology of the fungal cell, often 
rendering it susceptible to lysis and death.
19,20
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5.1.4 Results and discussions 
 
The results of the in vitro antimicrobial testing against selected Gram-positive bacteria, 
Gram-negative bacteria and fungi are reported in Table 5.1. The antimicrobial effect of 
DMSO against the test micro-organisms was investigated and no significant inhibitory effect 
was reported. To avoid any inhibitory effect DMSO was used at 1% (v/v).  
Data presented in Table 5.1 demonstrate that all the tested carbonyl complexes of the type 
[OsX2(CO)2(PR3)2] (1a, 2a-4b), with the exception of 1b, 1c and 3b, had little effect on 
growth inhibition of bacteria. Complex 1b, 1c and 3b show moderate activity against Gram-
negative Pseudomonas aeruginosa. In addition 3b showed bactericidal activity against 
Escherichia coli. The fungus Candida albicans was relatively resistant against the 
osmium(II) carbonyl complexes. Interestingly, the chlorido analogues showed moderate 
activity against Cryptococcus neoformans while the bromido and iodido showed little 
activity. This is consistent with the findings for Ru(II)-arene complexes [Ru(6-p-
cymene)X2(pta)], the Cl containing complexes inhibited growth of microorganisms and the 
Br and I bearing complexes were shown to exhibit little activity.
16
  The bromido and the 
iodido complexes were found to exhibit more DNA damage than other compounds in the 
series. If DNA damage is the contributing factor to toxicity then these compounds would be 
predicted to be the most active. Variation of phosphine ligands in the series 
[OsX2(CO)2(PR3)2] under study was found to exert no influence on the activity. It appears 
substitution of halide ligands influences the microbial activity of the test compounds.  
Complexes of the type cis/trans-[OsBr2(PP)2] exhibit moderate to good antibacterial 
activity. Data show that the trans complexes 6b and 7b are more active than the cis complex 
5b.  Compound 5b shows MIC values that is comparable to cis-[RuCl2(PP)2] (PP = dppm, 
dppe) against Mycobacterium tuberculosis.
21
  Furthermore, 6b appeared to be more active 
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than 7b against fungal strain Cryptococcus neoformans and Gram negative Escherichia coli 
and Pseudomonas aeruginosa.  
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Table 5.1: Minimum Inhibitory Concentration (MIC)
1
 of two Gram-negative, two Gram-positive and two fungal strains. 
Microorganisms C. neoformans C. albicans E.coli P. aeroginosa E. faecalis S. aureus 
Time (h) 24  48  24  48  24  48  24  48  24  48  24  48  
Complexes                                                                        MIC values (mg/mL) 
1a 0.063 0.031 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 
1b 0.063 0.250 0.250 0.250 0.250 0.250 0.250 0.063 0.250 0.250 0.250 0.250 
1c 0.250 0.250 0.250 0.250 0.250 0.250 0.063 0.250 0.250 0.250 0.250 0.250 
2a 0.031 0.063 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 
2b 0.125 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 
3a 0.063 0.031 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 
3b 0.031 0.250 0.250 0.250 0.031 0.031 0.016 0.031 0.031 0.063 0.031 0.250 
4a 0.125 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 
4b 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 0.250 
5b 0.016 0.250 0.250 0.250 0.031 0.031 0.016 0.016 0.016 0.250 0.125 0.250 
6b 0.004 0.031 0.250 0.250 0.004 0.004 0.002 0.002 0.002 0.250 0.002 0.250 
7b 0.008 0.016 0.063 0.031 0.016 0.016 0.004 0.004 0.004 0.031 0.004 0.031 
9 0.031 0.031 0.250 0.250 0.250 0.063 0.250 0.031 0.063 0.250 0.250 0.250 
10 0.016 0.031 0.031 0.063 0.250 0.125 0.031 0.063 0.031 0.250 0.031 0.250 
11 0.063 0.063 0.016 0.031 0.250 0.250 0.250 0.250 0.125 0.250 0.016 0.031 
Gentamycin - - - - 0.0008 0.0008 0.0002 0.0002 0.0008 0.0063 0.0004 0.0016 
Amphotericin 0.031 0.0125 0.0016 0.0031 - - - - - - - - 
                                                
1 MIC determined after 24 and 48 h incubation at 30 °C for fungi and 37 °C for bacteria. 
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The varying degree of antimicrobial activity of these derivatives depends either on the 
impermeability of the cells of the microbes or difference in ribosomes of microbial cells.
22
 
The effectiveness of 6b can be explained by overtone’s concept and chelation theory.23 
According to overtone’s concept of cell permeability, the lipid membrane surrounding the 
cell favours lipophilic compounds, due to which liposolubility is an important antimicrobial 
property.  On chelation, the -electrons in PP ligands are delocalized over the whole chelate 
ring and lipophilicity is enhanced which in turn increases membrane penetration of the 
complexes. In the ligand series evaluated in this study the tendency for chelation is greatest 
for dppe.
21
 Thus, 6b is expected to be more lipophilic and penetration enhanced hence it has a 
higher antimicrobial activity. The MIC values of 6b on Gram-negative Escherichia coli and 
Pseudomonas aeruginosa was very similar (though slighthly smaller) than those of the 
reference drug Gentamycin. 
Results show that Gram-positive bacteria and the fungal strain Candida albicans are resistant 
toward cluster complex 9. Moderate activity is observed against Gram-negative Escherichia 
coli and Pseudomonas aeruginosa and the fungal strain Candida albicans for complexes 10 
and 11. Though the complexes exhibit some activity, it does not reach the effectiveness of the 
reference agents used in this study at conditions under study. Fungicidal activity against the 
fungal strain Cryptococcus neoformans is observed. It appears in this series of the complexes 
evaluated, introduction of aromatic functionality had a particular influence on the overall 
inhibitory action of the complex against tested Candida albicans and Staphylococcus aureus 
strains.
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5.2 In vitro anticancer screening 
5.2.1 Introduction 
 
Cancer is the uncontrolled proliferation of genetically altered cells. Chemotherapy, surgery 
and radiotherapy are some of the methods used for treatment of cancer. Chemotherapy 
includes the use of cytotoxic agents to attack and destroy cancer cells. Platinum compounds 
have been the leading agents in cancer chemotherapy. 
The success of platinum compounds as anticancer agents has formed the basis for the study 
of metal based compounds as potential anticancer agents. As alternatives to the platinum 
compounds other transition metals have been explored and a number of metal complexes 
with potential application as anticancer agents have been developed.
24
 Ruthenium complexes 
appear to be the most promising alternative of platinum complexes.
25,26
  
The search for innovative metal-based drugs has focused on evaluation of the role of the 
central metal and coordinated ligands. The ligand exchange kinetics of Ru(III) complexes are 
very similar to the platinum(II) complexes. Ru complexes are less toxic compared to the 
platinum compounds. In contrast to platinum complexes, the ruthenium complexes have 
shown a selectivity for cancerous cells;
27,28
 this is thought to be due to the ability of 
ruthenium to mimic iron in binding to biomolecules. As cancer cells over-express transferrin 
because of demand for Fe, ruthenium-based compounds may be delivered more efficiently to 
cancer cells.
24,29
  
Ruthenium compounds are represented by three complexes which have successfully 
completed phase I clinical trail.
26,30,31
 NAMI-A a leading compound  that demonstrated 
antimetastatic activity,
31
 KP1019 and the Na analogue KP1339 exhibited activity against a 
wide range of primary tumours including the Cisplatin-resistant colorectal carcinoma.
26,30
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These Ru(III) complexes are thought to be pro-drugs activated in tumour to give the active 
species, postulated to be Ru(II) compounds.
26
 This theory has stimulated interest in the 
preparation of Ru(II) complexes as potential anticancer agents. Ru(II) arene complexes have 
been synthesized and anticancer activity evaluated. They have been found to be active both in 
vitro and in vivo. These complexes have been shown to undergo hydrolysis in a similar 
fashion to cisplatin, subsequently binding to nuclear DNA. Furthermore, extended arene 
ligands such as biphenyl are capable of intercalating between DNA bases.
32-34
 
Ruthenium complexes have shown potential which encouraged the continued search for other 
transition metals as alternatives to platinum complexes. Osmium belongs to the same group 
in the periodic table as ruthenium and is expected to possess similar biological activity. 
However, in comparison to ruthenium complexes, osmium complexes are more inert and 
have very slow hydrolysis rate. Nevertheless, osmium complexes have potential as anticancer 
agents. Hence, in this study a series of osmium complexes are screened for their potential 
activity as new anticancer agents. 
5.2.2 In vitro cytotoxicity studies 
 
The evaluation of preliminary anticancer activity of both synthetic and natural products on 
human cancer cell lines uses methods such as [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] (MTT) and Sulforhodamine B (SRB) assay methodologies. 
These assays give an indication of whole cell cytotoxicity, and thus to determine the exact 
biomolecular target would require further experiments to be performed. 
5.1.2.1 MTT assay 
MTT assay is a colorimetric assay used to assess cell metabolic activity. Its principle is based 
on the ability of living cells to reduce MTT, a yellow tetrazole, into purple formazan by 
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mitochondrial enzyme succinate dehydrogenase (Schme 5.1). The formazan formed is 
solubilised by addition of dimethylsulfoxide (DMSO) and determined 
spectrophotometrically. Thus, after treatment with anticancer agents it is possible to 
determine the number of cells that are living with respect to those cells that are untreated i.e 
control cells. The number of living cells can be plotted against different concentrations of the 
anticancer agents on x-axis.
35
 
 
  
Scheme 5.1: Reduction of MTT to formazan by cellular reductase enzyme. 
 
5.1.2.2 SRB assay 
The Sulforhodamine B (SRB) assay is used to measure drug-induced cytotoxicity and cell 
proliferation for drug screening applications. SRB is a bright pink aminoxanthene dye with 
two sulfonic groups (Figure 5.3). It has the ability to electrostatically bind to protein basic 
amino acid in a pH dependent environment. Under mild acidic conditions the dye binds and 
under mild basic conditions it is extracted from cells and solubilised for measurement. This 
assay is simple, accurate, reliable and reproducible. The method not only allows a large 
number of samples to be tested within a few days, but also requires only simple inexpensive 
reagents. The SRB assay is therefore an efficient and highly cost effective method for 
screening. 
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Figure 5.3: Structure of Sulforhodamine B (SRB) dye. 
 
In vitro anticancer activity of a total of 15 compounds have been investigated. This include 
12 organometallic complexes of the type [OsX2(CO)2(PR3)2] and [Os3(CO)12-n(PPh3)n]  (n = 2 
– 3), and 3 coordination complexes of the type [OsX2(PP)2] using SRB assay method.  
5.2.2.1 Materials and Methods 
 
Drugs and reagents 
The [OsX2(CO)2(PR3)2] complexes (X = Cl, Br, I; PR3 = tertiary phosphine) were prepared as 
described by Collman and Roper
36
 by carbonylation of [OsX6]
2-
 under pressurised CO gas in 
2-methoxyethanol with subsequent addition of the tertiary phosphine under reflux. 
The [OsX2(PP)2] complexes were prepared via microwave-promoted synthesis from 
hexahalo osmate salts Y2[OsX6] (Y = K, NH4; X = Cl, Br, I) in the presence of the 
corresponding bidentate phosphine ligand.  
Cluster complexes of the type [Os3(CO)12-n(PPh3)n] (n = 2-3) were prepared from Os3(CO)12 
using microwave promoted synthesis. 
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5.2.3 In vitro anticancer activity 
 
The in vitro anticancer activity of the synthesized complexes was determined using an SRB 
assay against 4 human cancer cell lines: renal (TK-10), melanoma (UACC-62), mammary 
adenocarcinoma (MCF-7) and HeLa cell lines. Parthenolide and Emetine were used as 
standards. Structures of the drugs used as standards are shown in Figure 5.5. 
 
Figure 5.4: Chemical structure of compounds used as standards. 
 
Parthenolide, a naturally occurring lactone, has recently attracted considerable attention 
because of its anticancer effects. The mechanism of action exerted by parthenolide has not 
been entirely elucidated. However, Yang and colleagues have attempted to define the mode 
of action in osteosarcoma cancer cells.
37
 They reported that parthenolide induces reactive 
oxygen species (ROS) as a consequence of increased autophagy and mitophagy.
37
 Cell death 
is a consequence of increased ROS. 
Emetine is a naturally occurring alkaloid. This compound has been shown to possess 
important biological activities that make it an important tool for pharmacologists and 
molecular biologists. Emetine has potential to inhibit DNA, RNA and protein synthesis. It is 
usually used to block protein synthesis in eukaryotic cells. It acts by blocking the early S 
phase of DNA replication.
38
 It irreversibly inhibits protein synthesis in HeLa cells by 
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depleting free ribosomes and subsequently increasing the polyribosomes.
39
 It binds to 40S 
ribosomal subunit.
40
 Further studies showed that the compound also inhibits DNA synthesis 
in HeLa cells irreversibly. The compound is also known to inhibit viral RNA synthesis in 
poliovirus infected HeLa cells.
39
   
5.2.4 Results and discussions 
 
The IC50 values, defined as the concentration corresponding to 50% growth inhibition, are 
represented in Table 5.2. The plot of log concentration versus percentage cell viability of 
complexes 1a-c, 2a-4b, 5b-7b, 9, 10 and 11 are depicted in Charts 5.1 – 5.5. 
A total of 15 compounds were screened against 4 different human cancer cell lines: TK-10 
(renal cell adenocarcinoma), UACC-62 (melanoma), MCF-7 (mammary adenocarcinoma) 
and HeLa cell line and a broad range of IC50 values were obtained. The IC50 values were in 
the range 3.46 to 100 M. In general, the carbonyl containing complexes (1a - c, 2a - 4b 
and 9 – 11) tested gave IC50  100M against the cancer cell lines under study and were 
defined as essentially inactive. Inactivity is likely because there is no ligand exchange with 
biomolecules or the hydrolysis rate is too slow. Hydrolysis is an essential prerequisite for 
biological activity for some compounds.
41-43
  
The active compounds were 5b, 6b and 7b with IC50 values in the range 4.25 – 40.97 M. In 
TK-10 cells complex 6b showed potency with IC50 value of  10 M and 5b and 7b showed 
a moderate effect (IC50 at range 10 - 50 M).  Complex 5b also showed a moderate effect 
against UACC-62 (IC50 = 26.38 M) and MCF-7 (IC50 = 25.01 M) cell line, respectively. 
Complex 6b and 7b showed comparable effect against the breast cancer cell line (MCF-7) 
and potency against UACC-62 was also observed. The activity of these complexes is 
comparable to that of the standard used. In vitro antitumour studies indicate greater 
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sensitivity of 6b towards UACC-62 than other cancer cell lines displaying IC50 values in 
lower concentrations. A higher activity was observed (IC50 = 4.25 M) compared to the 
standard, Parthenolide, with IC50 value of 5.76 M indicating the excellent cytotoxicity of 
this compound. A comparable cytotoxicity of 6b with parthenolide is observed against the 
TK-10 and MCF-7 cell line. 
Table 5.2: IC50 values of 1a-c, 2a-4b, 5b-7b and 9-11 towards TK-10, UACC-62, MCF-7 
and HeLa cell. 
Tissue  Renal Melanoma Breast Cervix 
Cell line  TK-10 UACC-62 MCF-7 HeLa 
Entry no. Complex                                           IC50 (M) 
1 1a 100 100 100 100 
2 1b 100 100 100 100 
3 1c 100 100 100 100 
4 2a 100 100 100 100 
5 2b 100 100 100 100 
6 3a 100 100 100 100 
7 3b 100 100 100 100 
8 4a 100 100 100 100 
9 4b 100 100 100 100 
10 5b 41.0 26.4 25.0 69.9 
11 6b 9.96 4.25 6.63 3.46 
12 7b 11.9 9.36 7.01 3.56 
13 9 100 100 100 100 
14 10 100 100 100 100 
15 11 100 100 100 100 
 Parthenolide 5.94 5.76 5.66 - 
 Emetine - - - 0.08 
 
Results show that complex 6b demonstrated the highest activity with an IC50 value of 4.25 
M against UACC-62, 9.96 M against TK-10 and 6.63 M against MCF-7 cell lines. The 
trans-[OsBr2(PP)2] (where PP = dppe, dppp) complexes exhibit higher anticancer activity 
against the three cell lines compared with the cis-[OsBr2(PP)2] isomer, with IC50 = 25.0 M 
against MCF-7, 26.4 M  against UACC-62 and 41.0 M against TK-10.  
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Under the experimental conditions used in this study the cytotoxicity on TK-10 cells 
followed the order 6b  7b   5b. The same order was followed for both UACC-62 and 
MCF-7 cancer cell lines. These compounds contain potentially labile Br ligands that can be 
cleaved to create a vacant coordination site at the metal centre. Cellular components such as 
DNA, proteins and enzymes have potential to then bind to this vacant site. The Os(II) metal 
ion is a soft acid and will interact with soft bases such as the sulfur containing amino acids. In 
addition to halide ligands the chelating phosphine ligands (dppm, dppe and dppp) which 
contain phenyl groups that have the potential to intercalate DNA bases.   
Structural modifications of the complexes could have significant effects on the antitumour 
activity of the complexes. In vitro potency of the trans-[OsBr2(PP)2] complex (where PP = 
dppe, dppp) increases with a decrease in alkyl chain between the donor P atoms. This can be 
explained by chelation theory and overtone’s concept of cell permeability.44  Liposolubility is 
greatest in dppe complex. Hence, it exhibits the highest activity in comparison to the dppp 
complex. Interestingly, the complex cis-[OsBr2(dppm)2] exhibited moderate cytotoxicity with 
IC50 higher than the trans isomers. This low activity suggests that the cis complex has a 
different mechanism of action compared to the trans complexes.  
The different anticancer activity observed of a single complex, as shown by the IC50 values, 
against the different human cancer cell lines might be related to the structural composition of 
the cell wall, since this is the first structural difference between the TK-10, UACC-62 and 
MCF-7 cell lines. Hence, we hypothesize that the different anticancer activity of the 
compounds against the different cancer cell lines could be explained by the ability to cross 
the membrane into the cell and interact, producing changes that eventually cause death of 
cancerous cells. Also the proliferation of any two different cell lines is expected to differ 
hence variation in the IC50 values is observed.  
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The compounds were further evaluated for general cytotoxicity on the HeLa cell line using 
SRB assay. Some of the complexes showed comparable cytotoxicity for tumour cells and 
HeLa cells. Compound 5b presented lower cytotoxicity on HeLa cell line (IC50 = 69.9 M) 
than TK-10, UACC-62 and MCF-7 (IC50 = 41.0, 26.4, 25.0 M). Compound 6b and 7b 
exhibited higher sensitivity towards HeLa cell (IC50 = 3.46, 3.56 M) than TK-10 (9.96, 11.9 
M), UACC-62 (4.25, 9.36 M) and MCF-7 cell line (IC50 = 6.63, 7.01 M), respectively. 
Complex 5b, 6b and 7b were all found to be significantly less cytotoxic relative to the 
Emetine standard.  
The cytotoxicity profiles of all the compounds clearly identified compound 6b as a potential 
candidate for further investigation, displaying IC50 values in lower concentrations against 
both UACC-62 and MCF-7 cells. Compound 6b is evidently more potent in inducing 
cytotoxicity compared to other derivatives. From the cell viability (%) vs complex 
concentration graph, a dose dependent activity was observed towards the cell lines. The 
results demonstrated that the complexes suppressed the growth rate in a dose-dependent 
manner. 
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Chart 5.1: The plot of log concentration versus percentage cell viability of 1a, 1b and 1c 
against TK-10, UACC-62 and MCF-7. 
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Chart 5.2: The plot of log concentration versus percentage cell viability of 2a, 2b, 3a and 3b 
against TK-10, UACC-62 and MCF-7. 
 
Chart 5.3: The plot of log concentration versus percentage cell viability of 4a and 4b against 
TK-10, UACC-62 and MCF-7. 
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Chart 5.4: The plot of log concentration versus percentage cell vialbility of 5b, 6b and 7b 
against TK-10, UACC-62 and MCF-7. 
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Chart 5.5: The plot of log concentration versus percentage cell vialbility of 9, 10 and 11 
against TK-10, UACC-62 and MCF-7. 
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5.3 Conclusions 
 
The microdilution assay revealed the effectiveness of the tested compounds on Gram-
positive, Gram-negative and fungal strains. These micro-organisms showed resistance against 
mononuclear Os(II) carbonyl complexes. A moderate antimicrobial activity was observed for 
Os(0) carbonyl cluster complexes with a coordinated PPh3 ligand. The non-substituted 
phosphine cluster complex [Os3(CO)12] exhibited little to moderate activity against fungal 
strains. Os(II) coordinate complexes of the type [OsX2(PP)2] generally exhibited good 
antimicrobial activity which is comparable with the reference antibiotics in some instances. 
The difference in degree of activity may be related to the ability of the compounds in 
penetrating the microbe cell wall. The proposed mechanism of action for the active 
[OsX2(PP)2] complex is protein synthesis inhibition because of selectivity of Gram-negative 
versus Gram-positive bacteria.  
Results from the SRB assay on TK-10, UACC-62 and MCF-7 cell lines show that 
compounds 5b, 6b and 7b exhibit antitumuor activity. Among these complexes compound 6b 
showed the highest potency with IC50 value  10 M against all cancer cell lines. This 
compound also showed a higher activity relative to the standard compound Parthenolide. 
Compound 7b was potent against the UACC-62 and MCF-7 cell lines and showed moderate 
activity against the renal cell line. The active compounds could be considered to be useful 
templates for further development to obtain more potent anticancer agents.  
Interestingly, compound 6b shows the highest antimicrobial and anticancer activity. Having 
both this activity is ideal because more often for some cancer patients, treatment weakens the 
immune system and the patient is more susceptible to other infections. Having the potential to 
inhibit the growth of microbes and cytotoxicity against cancerous cell could be beneficial. 
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Chapter 6 
Experimental 
 
6.1 General experimental details 
 
Carbonylation reactions were carried out in a Berghof Bar 845 autoclave. After carbonylation 
further manipulations were carried out under an inert atmosphere of argon using standard 
Schlenk techniques. The microwave irradiation experiments were undertaken in a Monowave 
900 microwave reactor using thick-walled 35 mL glass reaction vessel with Teflon-lined 
caps. All solvents used for microwave synthesis were used as received. The instrument used 
was programmed to reach the set temperature within a minute and maintain that temperature 
for the required time. In each case, the reactor was set to a maximum of 6 bar and high 
stirring rate was used. Caution was taken due to the toxic nature of metal carbonyl 
compounds. All manipulations were conducted under a highly efficient fume hood. The 
general cell culture technique and conditions for biochemical studies are as described in 
Section 6.4.Thin layer chromatography (TLC) was carried out on TLC Silica gel 60 F254 from 
Merck.  
6.2 Solvents and reagents 
 
Solvents were dried and distilled by standard literature procedures and stored in an 
atmosphere of argon. Dichloromethane and acetonitrile were distilled from calcium hydride. 
Methanol and 2-methoxyethanol were distilled from magnesium/iodine. Most chemicals were 
used as received, unless otherwise stated. 
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Potassium osmate K2[OsO2(OH)4] was obtained from Anglo Platinum Corporation. 
(NH4)2[OsCl6], (NH4)2[OsBr6] and K2[OsI6]  were prepared from K2[OsO2(OH)4] using the 
method reported by Chiririwa and Muzenda.
1
 Triphenylphosphine (P(C6H5)3), 
benzyldiphenylphosphine (Ph2P(CH2C6H5), tribenzylphosphine (P(CH2C6H5)3), 
tricyclohexylphosphine (P(C6H11)3), 1,1-bis(diphenylphosphino)methane (dppm), 1,2-
bis(diphenylphosphino)ethane (dppe), 1,3-bis(diphenylphosphino)propane (dppp), 1,4-
bis(diphenylphosphino)butane (dppb) were purchased from Sigma-Aldrich and used as 
received. 
6.3 Characterization techniques 
 
Infrared spectra were recorded on a Bruker vertex 70 FT-IR spectrophotometer. All 
measurements were conducted between 4000 and 400 cm
-1
. Spectra were recorded using 
dichloromethane as a solvent for cluster complexes (Chapter 4). Spectra was recorded in solid 
state (Chapter 2 and 3). Spectra obtained at spectral resolution of 4 cm
-1
. 
Raman studies were conducted on a Bruker vertex 70 FT-Raman spectrophotometer. All 
measurements were carried out between 4000 and 50 cm
-1
. Spectra obtained from solids at 
spectral resolution of 4 cm
-1
. 
NMR spectroscopic studies were recorded on Agilent spectrophotometer (300 MHz for 
1
H, 
75 MHz for 
13
C, 121 MHz for 
31
P) and data reported using the chemical shift scale in units of 
ppm relative to the solvent resonance: 
1
H CDCl3 7.24 ppm and 
13
C CDCl3 77.00 ppm. 
Spectral measurements recorded at room temperature.  
Thermal stability of the compounds was recorded on a Thermogravimetric Analysis SQ600 at 
temperatures ranges between 100 and 1300 °C at a heating rate of 10 °C/min. 
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Elemental analyses were carried out by Agricultural Research Council (ARC)-Institute for 
soil, climate and water 
Data collection and structure determinations were done by Prof A. Lemmerer at the 
University of the Witwatersrand. 
6.4 Biochemical studies 
 
6.4.1 In vitro antibacterial studies 
 
 The in vitro antimicrobial screening was done at the College of Agriculture and 
Environmental Science (CAES) at UNISA. 
6.4.1.1 Microorganism and reagents 
E. coli (ATCC 35218), P.aeruginosa (ATCC 7700), E. Faecalis (ATCC 19433), S. Aureus 
(ATCC 25925), C. Albicans (ATCC 24433) and C. Neoformans (ATCC 14116) were 
obtained from Davis dianostics. Gentamicin, Amphotericin B, p-iodonitrotetrazolium violet 
(p-INT)  and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich. Muller-Hilton 
(MH) agar, MH broth, Sabouraud dextrose agar and Sabouraud dextrose broth were obtained 
from Sigma-Aldrich. 
 
6.4.1.2 Antibacterial microdilution assay 
To determine the minimum inhibitory concentration (MIC) values for the test compounds a 
serial microdilution assay developed by Eloff was used.
2
 The test compounds were dissolved 
in an appropriate solvent (DMSO or acetone) to a concentration of 1 mg/mL and serially 
diluted up to 50% with water in a 96 well microtitre plate. The bacterial cultures were 
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maintained on Muller-Hilton (MH) agar at 4 °C and in MH broth at 37 °C. Growing bacterial 
organisms were transferred into a fresh MH broth and 100 L of these cultures were added to 
each well. The plates were incubated overnight at 37 °C in 100% relative humidity. DMSO 
was used as negative control and Gentamicin was used as a reference antibiotic and a positive 
control. About 40 L of 0.2 mg/mL INT was added to each well after incubation and the 
plates then incubated further at 37 °C for an additional 2 h. 
6.4.1.3 Antifungal microdilution assay 
For the antifungal assay a modified version of microdilution assay developed by Eloff and 
colleagues was used.
3
 The fungal strains were maintained in Sabouraud dextrose agar and 
Sabouraud dextrose broth prior to inoculation. Two-fold serial dilutions of the test compound 
were prepared as described above for bacteria. Growing fungal organisms were transferred 
into Sabouraud dextrose broth and 100 L of these cultures were added to each well. DMSO 
was used as neative control and Amphotericin-B was used as antifungal agent and positive 
control. 40 L of 0.2 mg/mL  INT was added to each well and the plates were incubated at 30 
°C for 24 h. The MIC was determined at the lowest sample concentration of compounds at 
which fungal growth was inhibited. 
 
6.4.2 Anticancer assay 
 
6.4.2.1 Tumor cell lines for in vitro tests 
The in vitro anticancer and cytotoxicity screening was done at the CSIR Biosciences 
Pharmacology division. The renal (TK-10), melanoma (UACC-62), breast (MCF-7) and Hela 
(ECACC) human cancer cell line were obtained from NCI (National Cancer Institute) and 
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maintained in Roswell Park Memorial Institute (RPMI) medium supplemented with 5% fetal 
bovine serum, 2 mM L-glutamine and 50 g/ml gentamicin. 
All cells were maintained in CO2 incubator with 5% CO2, 95% air and 100% relative 
humidity at 37 °C. Cell lines were routinely maintained as a monolayer cell. 
6.4.2.2 Cell viability 
Cells were inoculated on 96-well plates for 24 h before incubation with concentrations 
ranging from 100 - 0.01 M concentration of the compounds. Analysis was performed after 
24 h incubation period by Sulforhodamine B (SRB) viability test. The results are expressed as 
the concentrations inhibiting growth by 50% (IC50) after a 2-day incubation period after 
exposure to the complexes. The complexes were dissolved in DMSO just before incubation 
with cancer cells. Cells without drug addition were used as a control for the experiment. The 
cells with only medium were used as blanks.  
Drug induced cytotoxicity and cell proliferation was measured using the SRB assay 
developed by Skehan and collegues.
4
 Adherent cells were fixed with 50% cold trichloroacetic 
acid (TCA). After fixation TCA was washed, dried and dyed with SRB. Unbound dye was 
removed and bound stain was dissolved in 10 mM tris base (tris-hydroxymethyl-
aminomethane). Absorbance was read at 540 nm wavelength. 
6.5 Preparation of complexes 
6.5.1 General procedure for [OsX2(CO)2(PR3)2] 
 
Complex 1a-c, 2a-4b were synthesized according to the general method given below. The 
procedure has two parts, the first part involves carbonylation under pressurized gas (CO). The 
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second part is done under inert gas using Schlenk tube techniques. An excess of tertiary 
phosphine was used in the synthesis. 
 
Method: 
Into a 100 mL Teflon reaction cup equipped with a magnetic stirrer were placed hexahalo 
osmate salt [OsX6]
2-
 (where X = Cl, Br, I) and alcohol solvent and inserted into an autoclave. 
The reaction mixture was purged with ca. 5 bar carbon monoxide while stirring and finally 
pressurised to 10 bar at 140 °C for 48 h. The pressurized gas was vented after cooling to 
room temperature. An excess of tertiary phosphine ligand was weighed into a Schlenk tube 
and the pale yellow solution from reaction cup added. The mixture was heated to reflux and 
solution was left to cool to room temperature before filtering off the crude product (white 
solid). More product was obtained from the filtrate, concentrated under reduced pressure. The 
product was washed thoroughly with hexane and dried in vacuum. 
6.5.1.1 cis,cis,trans-[OsCl2(CO)2(PPh3)2] (1a)  
Reactants: (NH4)2[OsCl6] (0.20 g, 0.45 mmol), 2-methoxyethanol (50 mL) and PPh3 (0.34 g, 
1.30 mmol). Yield (0.25 g, 66%). Anal. Calc. For C38H30Cl2O2OsP2: C, 54.22 %; H, 3.59%; 
Found: C, 53.74%; H, 3.58%. Solid IR (CO): 2043(s), 1960(s) cm
-1
. Raman (Os-X)): 
308(vs), 284(vs) cm
-1
.  
1
H NMR (300 MHz, CDCl3):  7.87 (dt, J(HH) = 9.4, 5.3 Hz, 18H, H-
aromatic), 7.40 (dd, J(HP) = 3.7, 2.3 Hz, 12H, H-aromatic) ppm. 
13
C{H} NMR (75 MHz, 
CDCl3):  172.88 (t, J(PC) = 7.1 Hz, carbonyl C), 134.35 (t, J(PC) = 5.2 Hz, ortho C, phenyl), 
131.13 (d, J(PC) = 26.9 Hz, ipso C, phenyl), 130.63 (s, para C, pheny), 128.16 (t, J(PC) = 5.1 
Hz, meta C, phenyl) ppm. 
31
 P{H} NMR (121 MHz, CDCl3):  -10.21 (s) ppm. TGA (on set 
of decomposition): 315 °C. 
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6.5.1.2 cis,cis,trans-[OsBr2(CO)2(PPh3)2] (1b) 
 (NH4)2[OsBr6] (2.07 g, 2.93 mmol), 2-methoxyethanol (40 mL) and PPh3 (2.07 g, 7.89 
mmol). Yield (2.20 g ,81%). Anal. Calc. For C38H30Br2O2OsP2: C, 49.04%; H, 3.25%; 
Found: C, 47.59%; H, 3.13%. Solid IR (CO): 2041(s), 1960(s) cm
-1
. Raman ((Os-X) ): 
229(vs), 210(s) cm
-1
. 
1
H NMR (300 MHz, CDCl3):  7.89 (ddd, J(HP) = 9.8, 6.4, 3.4 Hz, 12H, 
H-aromatic), 7.48 – 7.30 (m, 18H, H-aromatic) ppm. 13C{H}NMR (75 MHz, CDCl3):  
171.66 (t, J(PC) = 7.1 Hz, C carbonyl), 134.90 (t, J(PC) = 5.0 Hz, ortho C, phenyl), 131.86 (t, 
J(PC) = 27.1 Hz, ipso C, phenyl), 130.72 (s, para C, phenyl), 127.82 (t, J(PC) = 5.2 Hz, meta C, 
phenyl) ppm. 
31
 P{H} NMR (121 MHz, CDCl3): -17.15 (s) ppm. TGA (on set of 
decomposition): 313 °C. 
6.5.1.3 cis,cis,trans-[OsI2(CO)2(PPh3)2] (1c) 
K2[OsI6] (1.18 g, 1.14 mmol), 2-methoxyethanol (50 mL) and triphenylphosphine (0.89 g, 
4.88 mmol). Yield (0.81 g, 69%).Solid IR (CO ): 2033(s), 1962(s) cm
-1
. Raman ((Os-X)): 
174(vs), 157(vs) cm
-1
. 
1
H NMR (300 MHz, CDCl3):  8.00 – 7.67 (m, 12H, H-aromatic), 7.67 
– 7.30 (m, 18H, H-aromatic) ppm. 13C{H} NMR (75 MHz, CDCl3):  169.93 (t, J(PC) = 6.7 
Hz, C carbonyl), 134.90 (t, J(PC) = 4.8 Hz, ortho C, phenyl), 131.86 (t, J(PC) = 27.1 Hz, ipso C, 
phenyl), 130.72 (s, para C, phenyl), 127.82 (t, J(PC) = 5.2 Hz, meta C, benzyl) ppm. 
31
 P{H} 
NMR (121 MHz, CDCl3):  -28.44 (s) ppm. TGA (on set of decomposition): 299 °C 
 
6.5.1.4 cis,cis,trans-[OsCl2(CO)2{Ph2P(CH2C6H5)}2] (2a) 
 (NH4)2[OsCl6] (0.20 g, 0.46 mmol), 2-methoxyethanol (40 mL) and 
benzyldiphenylphosphine (0.33 g, 1.19 mmol). Yield (0.25 g, 63%). Anal. Calc. For 
C40H34Cl2O2OsP2: C, 55.24%; H, 3.94%; Found: C, 55.40%; H, 3.90%. Solid IR (CO): 
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2036(s), 1962(s) cm
-1
. Raman ((Os-X)): 312(s), 285(m) cm
-1
. 
1
H NMR (300 MHz, CDCl3): 
7.75 – 7.57 (m, 8H, H-aromatic), 7.49 – 7.18 (m, 12H, H-aromatic), 6.93 (dt, J(HH) = 25.2, 
7.2 Hz, 6H, H-aromatic), 6.61 (d, J(HH) = 7.1 Hz, 4H, H-aromatic), 4.41 (t, J(HP) = 4.4 Hz, 4H, 
2  CH2 benzyl) ppm. 
13
C{H} NMR (75 MHz, CDCl3):  172.52 (t, J(PC) = 6.8 Hz, C 
carbonyl), 133.55 (t, J(PC) = 5.7 Hz, ipso C, benzyl), 133.40 (t, J(PC) = 4.9 Hz, ortho C, 
phenyl), 130.73 (s, para C, phenyl), 130.45 (s, ortho C, benzyl), 129.14 (t, J(PC) = 25.5 Hz,  
ipso C, phenyl), 128.15 (t, J(PC) = 5.0 Hz, meta C, phenyl), 127.70 (s, meta C, benzyl), 126.12 
(s, para C, benzyl), 29.14 (t, J(PC)= 13.1 Hz, CH2, benzyl) ppm. 
31
 P{H} NMR (121 MHz, 
CDCl3):  -3.80 (s) ppm. TGA (on set of decomposition): 330 °C. 
 
6.4.1.5 cis,cis,trans-[OsBr2(CO)2{Ph2P(CH2C6H5)}2] (2b) 
 (NH4)2[OsBr6] (2.00 g, 2.83 mmol), 2-ethoxyethanol (70 mL) and benzyldiphenylphosphine 
(2.16 g, 7.82 mmol). Yield (1.50 g, 55%). Solid IR ((CO)): 2040(s), 1970(s) cm
-1
. Raman 
((Os-X)): 210(vs), 190(s). 
1
H NMR (300 MHz, CDCl3): 7.69 (dd, J(HP) = 6.7, 13.8 Hz, 8H, 
H- aromatic), 7.30 (dd, J(HH) = 24.0, 3.7 Hz, 12H, H-aromatic), 6.92 (dt, J(HH) = 15.0, 7.2 Hz, 
6H, H-aromatic), 6.60 (d, J(HH) = 7.2 Hz, 4H, H-aromatic), 4.56 (t, J(HP) = 4.3 Hz, CH2 
benzyl) ppm. 
13
C{H} NMR (75 MHz, CDCl3):  171.45 (t, J(PC) = 6.8 Hz, C carbonyl), 
134.10 (t, J(PC) = 5.4 Hz, ipso C, benzyl), 133.63 (t, J(PC) = 4.8 Hz, ortho C, phenyl), 130.70(s, 
para C, phenyl), 130.43 (s, ortho C, benzyl), 129.12 (t, J(PC) = 25.8 Hz, ipso C, phenyl), 
128.01 (t, J(PC) = 4.9 Hz, meta C, phenyl), 127.70 (s, meta C, benzyl), 126.08 (s, para C, 
benzyl), 31.61 (t, J(PC) = 13.9 Hz, CH2, benzyl) ppm. 
31
 P{H} NMR (121 MHz, CDCl3):   -
11.04 (s) ppm. TGA (on set of decomposition): 197 °C. 
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6.4.1.6 cis,cis,trans-[OsCl2(CO)2{P(CH2C6H5)3}2] (3a)  
 (NH4)2[OsCl6] (0.20 g, 0.46 mmol), 2-methoxyethanol (40 mL) and  tribenzylphosphine 
(0.38 g, 1.18 mmol) .Yield (0.43 g, 63%). Solid IR ((CO)): 2034(s), 1960(s) cm
-1
. Raman 
((Os-X)):  311(vs), 305(vs) cm
-1
. 
1
H NMR (300 MHz, CDCl3): 7.46 – 7.15 (m, 18H, H-
aromatic), 7.15 – 6.98 (m, 12H, H-aromatic), 3.61 (t, J(HP) = 3.8 Hz, 6H, 3CH2 benzyl) ppm. 
13
C{H} NMR (75 MHz, CDCl3):  172.52 (t, J(PC)= 7.1 Hz, C carbonyl), 133.93 (t, J(PC)= 2.9 
Hz, ipso C, benzyl), 130.53 (t, J(PC) = 2.3 Hz, ortho C, benzyl), 128.81 (s, meta C, benzyl), 
127.01 (s, para C, benzyl), 30.53 (t, J(PC) = 13.3 Hz, CH2, benzyl) ppm. 
31
P{H} NMR (121 
MHz, CDCl3):  -12.97 (s) ppm. TGA (on set of decomposition): 332 °C. 
6.5.1.7 cis,cis,trans-[OsBr2(CO)2{P(CH2C6H5)3}2] (3b) 
 (NH4)2[OsBr6] (0.41 g, 0.58 mmol), 30 mL 2-ethoxyethanol and tribenzylphosphine (0.44 g, 
1.44 mmol). Yield (0.33 g,56%). Anal. Calcd for C40H34Br2O2OsP2: C, 52.08%; H, 4.17; 
Found: C, 51.93%; H, 4.10%. Solid IR ((CO)): 2023(s), 1953(s) cm
-1
. Raman ((Os-X)): 
216(vs), 189(vs) cm
-1
. 
1
H NMR (300 MHz, CDCl3):  7.24 (dd, J(HH) = 6.5, 3.6 Hz, 18H, H-
aromatic), 7.08 – 6.93 (m, 12H, H-aromatic), 3.72 (t, J(HP)= 3.8 Hz, 12H, 3CH2 benzyl) ppm. 
13
C{H} NMR (75 MHz, CDCl3):  171.74 (t, J(PC) = 7.1 Hz, C carbonyl), 134.27 (t, J(PC) = 
3.0 Hz, ipso C, benzyl), 130.46 (t, J(PC) = 2.3 Hz, ortho C, benzyl), 128.81 (s, meta C, 
benzyl), 127.00 (s, para C, benzyl), 32.16 (t, J(PC) = 13.7 Hz, CH2 benzyl) ppm. 
31
 P{H} 
NMR (121 MHz, CDCl3):  -23.17 (s) ppm. TGA (on set of decomposition): 299 °C. 
6.5.1.8 cis,cis,trans-[OsCl2(CO)2(PCy3)2] (4a) 
 (NH4)2[OsCl6] (0.30 g, 0.68 mmol), 2-methoxyethanol (40 mL) and tricyclohexylphosphine 
(0.48 g, 1.71 mmol). Yield (0.49 g, 67%.) Solid IR ((CO)): 2010 (s), 1933 (s) cm
-1
. Raman 
((Os-X)):  305(s), 281(s) cm
-1
. 
1
H NMR (300 MHz, CDCl3):  2.61 (s, 6H), 2.15 (d, J(HH) = 
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12.8 Hz, 12H), 1.80 – 1.36 (m, 32H), 1.31 (t, J(HH) = 8.6 Hz, 16H) ppm. 
13
C{H} NMR (75 
MHz, CDCl3):  176.91 (t, J = 7.3 Hz, carbonyl), 33.98 (t, J(PC) = 11.7 Hz, virtual triplet), 
29.32(s), 27.64 (t, J(PC) = 5.1 Hz, virtual triplet), 26.30 Hz (s) ppm.  
31
 P{H} NMR (121 MHz, 
CDCl3):  -2.63(s) ppm. TGA (on set of decomposition): 306 °C. 
6.5.1.9 cis,cis,trans-[OsBr2(CO)2(PCy3)2] (4b) 
 (NH4)2[OsBr6] (2.04 g, 2.89 mmol), 70 mL 2-ethoxyethanol and tricyclohexylphosphine 
(3.39 g, 12.1 mmol) . Yield (2.57 g, 92 %). Solid IR ((CO)): 2012(s), 1939(s) cm
-1
. Raman 
((Os-X)): 221(vs), 189(m) cm
-1
. 
1
H NMR (300 MHz, CDCl3):  2.66 (d, J(HP) = 11.8 Hz, 6H), 
2.19 (d, J(HH) = 11.8 Hz, 6H), 1.93 – 1.48 (m, 16H), 1.43 – 1.16 (m, 8H) ppm. 
13
C{H} NMR 
(75 MHz, CDCl3):  175.66 (t, J(PC) = 7.3 Hz, C carbonyl), 34.89 (t, J(PC) = 11.8 Hz, virtual 
triplet), 29.66(s), 27.55 (t, J(PC) = 5.1 Hz, virtual triplet), 26.30 Hz (s) ppm.  
31
 P{H} NMR 
(121 MHz, CDCl3):  -10.57 (s) ppm. TGA (on set decomposition): 286 °C. 
6.5.2 General procedure for [OsX2(PP)2] using microwave mediated synthesis 
 
Excess diphosphine ligand and the hexahaloosmate, [OsX6]
2-
 (X = Cl, Br, I) (1.0 mmol) were 
placed in a 35 mL reaction vessel equipped with a magnetic stirrer bar. To this mixture 2-
methoxyethanol (10 mL) was added and the reaction vessel was irradiated with microwaves 
at constant power of 200 W. A temperature of 80 °C was maintained for 15 min. A brown-
yellow solution was filtered to remove any unreacted solid starting material. The solvent was 
removed under reduced pressure and the residue was washed with hexane. The product was 
obtained as a yellow product. 
6.5.2.1 cis-[OsCl2(dppm)2] (5a) 
 (NH4)2[OsCl6] (0.20 g, 0.46 mmol) and  dppm (0.71 g, 1.87 mmol). Yield (0.19 g, 40%). 
Solid IR (cm
-1
): 3055 (PhH), 2913 (CH), 1572 (C=C), 1090 (P-Ar). 
1
H NMR (300 MHz, 
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CDCl3): 8.12 (s, 4H, H-aromatic), 7.69 (s, 2H, H-aromatic), 7.40 (d, J(HH) = 5.2 Hz, 6H, H-
aromatic), 7.25 – 6.81 (m, 18H, H-aromatic), 6.72 (s, 4H, H-aromatic), 6.47 (s, 6H, H-
aromatic), 5.90 (s, 2H, -CH2-), 4.40 (s, 2H, -CH2-). TGA (on set of decomposition): 370 °C. 
cis-[OsBr2(dppm)2] (5b) 
 (NH4)2[OsBr6] (0.20 g, 0.28 mmol) and dppm (0.45 g, 1.17 mmol). Yield (0.10g, 91%). 
Solid IR (cm
-1
): 3070 (PhH), 2984 (CH), 1572 (C=C), 1093 (P-Ar). 
1
H NMR (300 MHz, 
CDCl3):  8.22 (dd, J(HH) = 12.2, 5.3 Hz, 4H, H-aromatic), 7.94 (dd, J (HH) = 11.6, 5.7 Hz, 4H, 
H-aromatic), 7.48 – 6.92 (m, 20H, H-aromatic), 6.80 (dt, J(HH) = 14.0, 8.3 Hz, 8H), 6.68 – 
6.56 (m, 4H, H-aromatic), 6.02 – 5.85 (m, 2H, -CH2-), 4.87 – 4.69 (m, 2H, -CH2-) ppm. 
31
P{H} NMR (121 MHz, CDCl3): -57.9 (t, J(PP) = 23.1 Hz), -72.8 (t, J(PP) = 23.1 Hz) ppm. 
TGA (on set of decomposition): 376 °C. 
6.5.2.3 cis-[OsI2(dppm)2] (5c) 
K2[OsI6] (0.21 g, 0.20 mmol) and dppm (0.33 g, 0.86 mmol). Yield (0.17 g, 68%). Solid IR 
(cm
-1
): 3045 (PhH), 2913 (CH), 1584 (C=C), 1090 (P-Ar). 
1
H NMR (300 MHz, CDCl3): 
8.20 (dd, J(HH) = 12.2, 5.3 Hz, 4H, H-aromatic), 8.03 (dd, J(HH) = 8.2, 4.6 Hz, 4H, H-
aromatic), 7.45 – 6.81 (m, 24H, H-aromatic), 6.70 (dt, J(HH) = 17.7, 7.4 Hz, 8H, H-aromatic), 
6.19 – 6.02 (m, 2H, -CH2-), 4.99 – 4.84 (m, 2H, -CH2-) ppm. 
31
P{H} NMR (121 MHz, 
CDCl3): -64.4 (t, J(PP) = 2.3  Hz), - 83.5 (t, J(PP) = 22.3  Hz) ppm. TGA (on set of 
decomposition): 340 °C. 
6.5.2.4 trans-[OsCl2(dppe)2] (6a) 
 (NH4)2[OsCl6] (0.21 g, 0.48 mmol) and dppe (0.77 g, 1.93 mmol). Yield (0.24 g, 48%). Solid 
IR (cm
-1
): 3052 (PhH), 2917 (CH), 1585 (C=C), 1090 (P-Ar). 
1
H NMR (300 MHz, CDCl3): 
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7.65 – 6.72 (m, 40H, H-aromatic), 2.29 (s, 8H, 2-CH2CH2-)TGA (on set of 
decomposition):  347 °C. 
6.5.2.5 trans-[OsBr2(dppe)2] (6b) 
 (NH4)2[OsBr6] (0.20 g, 0.28 mmol) and dppe (0.47 g, 1.18 mmol). Yield (0.27 g, 82%), Solid 
IR (cm
-1
): 3071 (PhH), 2922 (CH), 1585 (C=C), 1088 (P-Ar). 
1
H NMR (300 MHz, CDCl3): 
7.53 – 7.13 (m, 8H, H-aromatic), 7.10 (d, J(HH) = 28.5 Hz, 32H, H-aromatic), 2.30 (d, J(HH) 
= 64.1 Hz, 8H, 2  -CH2CH2-) ppm.
31
P{H} NMR (121 MHz, CDCl3): 29.5 (s) ppm. TGA 
(on set of decomposition): 325 °C. 
6.5.2.6 trans-[OsI2(dppe)2] (6c) 
K2[OsI6] (0.21 g, 0.20 mmol) and dppe (0.34 g, 0.85 mmol). Yield (0.21 g, 81%). Solid IR 
(cm
-1
): 3050 (PhH), 2950 (CH), 1583 (C=C), 1087 (P-Ar). 
1
H NMR (300 MHz, CDCl3):  
7.35 – 7.16mH-aromaticd, J(HH) = 7.5 Hz, 12H, H- aromatic), 6.99 (dt, J(HH) = 
14.9, 7.6 Hz, 16H, H-aromatic), 2.67 (s, 4H, -CH2CH2-), 2.12 (s, 4H, -CH2CH2-). 
31
P{H} 
NMR (121 MHz, CDCl3): 26.5 (s).  TGA (on set of decomposition): 336 °C. 
6.5.2.7 trans-[OsCl2(dppp)2] (7a) 
 (NH4)2[OsCl6] (0.20 g, 0.45 mmol) and dppp (0.77 g, 1.87 mmol). Yield (0.22, 44%). Solid 
IR (cm
-1
): 3046 (PhH), 2925 (CH), 1588 (C=C), 1090 (P-Ar). 
1
H NMR (300 MHz, CDCl3): 
7.64 – 7.50 (m, 15H, H-aromatic), 7.30 – 7.19 (m, 15H, H-aromatic), 7.14 (s, 18H, H-
aromatic), 7.00 (s,12H, H-aromatic), 3.55 (s, 12H, -CH2-) ppm. TGA (on set of 
decomposition): 289 °C. 
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6.5.2.8 trans-[OsBr2(dppp)2] (7b) 
 (NH4)2[OsBr6] (0.20 g, 0.28 mmol) and dppp (0.48 g, 1.16 mmol). Yield (0.14 g, 52%). 
Solid IR (cm
-1
): 3047 (PhH), 2912 (CH), 1585 (C=C), 1091 (P-Ar). 
1
H NMR (300 MHz, 
CDCl3): 7.42 – 7.23 (m, 15H, H-aromatic), 7.08 (tt, J(HH) = 20.2, 7.2 Hz, 15H, H-aromatic ), 
6.88 (t, J (HH) = 7.6 Hz, 10H, H-aromatic), 3.16 – 2.99 (m, 6H, 3-CH2-), 2.45 – 2.30 (m, 6H, 
3-CH2-) ppm. 
31
P{H} NMR (121 MHz, CDCl3):  -25.3 (s) ppm.TGA (on set of 
decomposition): 279 °C. 
6.5.2.9 trans-[OsI2(dppp)2] (7c) 
K2[OsI6] (0.20 g, 0.19 mmol) and dppp (0.32 g, 0.77 mmol). Yield (0.10 g, 42%). Solid IR 
(cm
-1
): 3071 (PhH), 2940 (CH), 1585 (C=C), 1089 (P-Ar). 
1
H NMR (300 MHz, CDCl3): 7.48 
– 7.15 (m, 10H, H-aromatic), 7.1 (d, J(HH) = 7.5, 15H, H-aromatic), 6.99 (dt, J (HH) = 14.9, 7.6 
Hz, 15H), 2.67 (s, 6H, -CH2-), 2.12 (s, 6H, -CH2-) ppm. 
31
P{
1
H} NMR (121 MHz, CDCl3): 
32.4(s) ppm. TGA (on set of decomposition): 263 °C. 
6.5.3 Preparation of triosmium clusters and phosphine substituted derivatives 
 
6.5.3.1 Preparation of [Os3(CO)12] (9) 
 (NH4)2[OsCl6] (2.03 g, 4.62 mmol) and zinc (4.62 g, 88.37 mmol) were placed in an 
autoclave Teflon cup. Dry methanol (30 mL) was added and placed in the autoclave. The 
reaction mixture was purged three times with ca. 10 bar CO while stirring. Finally 
pressurized to 55 bar at 50 °C. After 24 h the autoclave was switched off and cooled to room 
temperature before venting the pressurized gas. Yellow crystalline material was filtered and 
washed with acetone. Yield (0.89 g, 64%). Anal Calc for C12O12Os3: C, 15.89%; Found: C, 
15.90%. IR (CH2Cl2) (CO):  2067, 2037, 2015, 1995 cm
-1
. Raman (CO) : 2127, 2068, 2025, 
2002 cm
-1
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6.5.3.2 Preparation of Os3(CO)12-n(PR3)n (PR3 = PPh3, n = 2-3) via microwave. 
A sample of Os3(CO)12 (0.20 g, 0.22 mmol) and triphenylphosphine (0.23 g 0.88 mmol) were 
placed in a 35 mL reaction vessel equipped with a magnetic stirrer bar . Acetonitrile (20 mL)  
was added and reaction mixture irradiated with microwaves at a constant power of 200 W 
and high stirring rate. A reaction temperature of 80 °C was maintained for 2 min. Upon 
cooling the crude product precipitated as an orange-red solid. TLC was performed with an 
eluent of 1.7:1 hexane: CH2Cl2 to give 0.20 g (67.0%) of orange [Os3(CO)10(PPh3)2]  (11), Rf 
= 0.71, and 0.12 g (33.0%) of orange-red [Os3(CO)9(PPh3)3] (10), Rf = 0.44. The IR 
(CH2Cl2), 
1
H NMR and 
31
P{H} NMR of complex 9 were identical to those previously 
published.
5
 Spectral data for 9: IR (CH2Cl2) (CO): 2084 (w), 2055(m), 2029(m), 1996(s), 
1968(mw) cm
-1
. Solid Raman CO): 2077(vs), 2029(w), 2020(m), 1991(s), 1967(s), 1959(s) 
cm
-1
. 
1
H NMR (300 MHz, CDCl3): 7.51 – 7.27 (m, 30H, H-aromatic) ppm. 
31
P{H} NMR 
(121 MHz, CDCl3): -1.76 (s) ppmSpectral datafor 10: IR (CH2Cl2) CO): 2067(w), 
2049(w), 2023(m), 2019(m), 1996(m), 1987(mw), 1969(mw) cm
-1
. Solid Raman CO): 2050 
(s), 1989(vs), 1967 (vs), 1950 (m), 1924 (m), 1918 (mw) cm
-1
. 
1
H NMR (300 MHz, CDCl3): 
7.45 – 7.31 (m, 45H, H-aromatic) ppm. 31P{H} NMR (121 MHz, CDCl3): -2.29 (s) ppm.  
6.5.3.2 Preparation of [Os3(CO)11(dppm)] (12) 
A sample of [Os3(CO)12] (0.11 g, 0.12 mmol)  and dppm (0.10 g, 0.26 mmol) were placed in 
a  35 mL glass reaction vessel equipped with magnetic stirrer bar. MeCN (10 mL) was added 
and the reaction mixture was irradiated with microwaves at constant power of 850 W. A 
temperature of 80 °C was maintained for 2 min. The yellow solution was obtained. The 
solvent was removed under reduced pressure and residue washed with hexane 3  10 mL. 
Yield (0.09 g, 60%). IR (CH2Cl2) (CO): 2074(w), 2069(mw), 2057(m), 2020(m), 1999(m), 
1974(w) cm
-1
. 
1
H NMR (300 MHz, CDCl3): 7.90 – 6.60 (m, 20H, H-aromatic), 4.82 (d, J = 
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7.8 Hz, 2H, -CH2-) ppm. 
31
P{H} NMR (121 MHz, CDCl3): -20.25 (dd, JPC =49.1 Hz ), -
23.60 (dd, JPC = 49.1 Hz) ppm. 
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